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ABSTRACT OF THE DISSERTATION
NEUROBIOLOGICAL IMPACT OF HIV INFECTION AND CHRONIC CANNABIS
USE
by
Jessica S. Flannery
Florida International University, 2021
Miami, Florida
Professor Matthew T. Sutherland, Major Professor
Neuroimaging research has identified brain alterations linked with the human
immunodeficiency virus (HIV) that contribute to cognitive declines characterizing the
disease. Given cannabis’s (CB’s) anti-inflammatory properties, use prevalence among
people living with HIV (PLWH), and impact on neurocognition, my dissertation utilizes a
between-groups study design to interrogate separate and interactive effects of HIV and
CB on fMRI measures of brain activity. We investigate (1) task-based brain activity at
the regional-level, (2) insular resting-state functional connectivity (rsFC) at the circuitlevel, and (3) large-scale brain network interactions at the systems-level. Participants
(N=114) were stratified into four groups (HIV+/CB+; HIV+/CB-; HIV-/CB+; HIV-/CB-)
and underwent fMRI scanning while completing an Error Awareness Task (EAT) and
while at rest. Participants also completed a battery of instruments including subjective
reports of cognitive failures, and objective measures of cognition and medication
management abilities. Blood samples quantified disease severity (viral load) and
inflammation (tumor necrosis factor alpha [TNF-a]). Regarding task-based brain activity,
PLWH displayed a lack of error-related deactivation in two default mode network
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(DMN) regions (posterior cingulate cortex [PCC], medial prefrontal cortex [mPFC]).
Across all participants, reduced error-related PCC deactivation correlated with reduced
medication management abilities and mediated the effect of HIV on such abilities.
Regarding insular circuitry, we observed interactive HIVxCB effects on rsFC between
two anterior insula (aI) subregions and sensorimotor cortices such that, CB use
normalized altered rsFC that was observed among non-using PLWH and correlated with
decreased somatic complaints and increased inflammation. Finally, regarding large-scale
network interactions, PLWH displayed increased salience network (SN)-DMN rsFC that
was associated with diminished error-awareness. These results demonstrate that
insufficient error-related DMN suppression and heightened SN-DMN rsFC are linked
with HIV and have consequences for error-processing and medication management.
Additionally, these outcomes suggest a potential normalizing effect of CB on altered
insula-sensorimotor neurocircuitries among PLWH and begin to elucidate inflammatory
mechanisms through which CB use may impact brain function in the context of HIV.
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INTRODUCTION
Human immunodeficiency virus (HIV) remains a public health concern with an
estimated 1.2 million people in the United States living with the disease [1]. While annual
new diagnoses and deaths among people living with HIV (PLWH) have significantly
decreased in the past decade [2], the inflection still significantly impacts quality of life and
kills thousands of Americans each year [1]. HIV attacks the immune system causing
chronic inflammation and increased risk of opportunistic infections [3, 4]. Additionally,
the virus crosses the blood brain barrier, infects cells in the central nervous system (CNS),
and can lead to neuroinflammation and neural degeneration [5-7]. Even with widespread
availability of antiretroviral therapy (ART), approximately 30–50% of PLWH are
impacted by neurocognitive alterations [8, 9]. Neuroimaging research has identified
structural and functional brain alterations that are linked with HIV infection [10-15] and
thought to contribute to the progressive cognitive declines characterizing the disease [8, 9,
16-21].
Additionally, substance use is prevalent among PLWH [22, 23] and may exasperate
the impact of HIV on the brain. In particular, both recreational and medical cannabis (CB)
use is common among PLWH, with 77% reporting lifetime use [24-29]. Medical CB use
currently has been decriminalized in 34 states [30, 31] leading to greater availability and
reduced disapproval of use. Given recent changes in societal views, state laws, and clinical
practice, CB use, in general, has continued to increase over the past decade with ~45% of
Americans over the age of 12 reporting lifetime use and 15% reporting use in the last year
[32]. Some evidence suggests that CB use can decrease inflammation among PLWH [28,
33-35] and may reduce HIV-related pain and gastrointestinal symptoms such as loss of
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appetite, nausea, and weight loss [36-38]; however, the perceived versus actual
effectiveness has yet to be fully disentangled [39-42]. Additionally, despite potential CBrelated anti-inflammatory and medical benefits, evidence also suggests that use may lead
to further cognitive impairments among PLWH [40, 43].
The limited research on CB use in the context of HIV infection has demonstrated
that the interacting consequences are complicated, and at times, dependent on CB use
amount, duration, or other characteristics of use history [40, 44, 45]. For example, one
study demonstrated that while CB using PLWH had a lower viral load and higher CD4+
cell count than non-using PLWH, they also displayed decreased learning and memory
performance compared to both non-using PLWH and using HIV- participants [40]. Further,
some evidence suggests that duration of CB use among men living with HIV is associated
with worsening impairments in processing speed and cognitive flexibility over time [46].
Additionally, PLWH that started regularly using CB prior to age 18 were over 8 times more
likely to demonstrate learning impairments and nearly 4 times more likely to demonstrate
memory impairments when compared to non-using and late onset using PLWH [45]. The
impact of CB use on learning, memory, and cognition among PLWH may also be
dependent on the heaviness of use [40, 44] and whether CB use was initiated before or after
HIV seroconversion [47]. Further, relationships between cognitive performance and CB
use heaviness may differ among PLWH compared to controls [40, 44]. Despite these
emergent and nuanced findings, the neurobiological impact of CB use in the context of
HIV, is still not completely understood.
Additionally, there is growing appreciation that neurocognitive behavioral
measures alone may not provide a complete perspective on potential neurobiological
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impacts of HIV and CB [47, 48]. Indeed, atypical brain activity among PLWH, measured
via functional magnetic resonance imaging (fMRI) may precede observable declines in
cognition and diagnoses of HIV-associated neurocognitive disorder (HAND) [48]. Given
known effects of CB and HIV on neurocognitive functioning, it is reasonable to suspect
that CB using PLWH may incur interacting or compounding effects on both brain and
behavior. Evidence links chronic CB use with deficits in some of the same brain systems
and cognitive functions that are altered among PLWH [17, 18, 49, 50]. On the other hand,
some emerging evidence suggests a normalizing effect of CB use on HIV-associated
functional brain alterations [51, 52]. As such, the beneficial versus harmful effects of CB
use on the brain and behavior of PLWH remains to be fully delineated.
Accumulating neuroimaging findings suggest that the insula may be of particular
importance when considering interactive HIV and CB effects. Elevated task-related insula
activity among PLWH [53], and reduced error awareness-related insula activity among CB
users [54], has been documented. Additionally, insula function has been linked with
inflammation [51, 55, 56] and one study not only demonstrated distinct HIV and CB effects
on left anterior insula (aI) activity during a cognitive interference task, but also displayed
a HIV by CB interaction such that CB use appeared to normalize reduced aI activity among
PLWH [51]. As the insula has been repeatedly implicated in error monitoring and error
awareness [53, 54, 57], we aimed to probe task-based insula activity by employing the
Error Awareness Task (EAT), a modified Go/NoGo paradigm that allows for assessment
of distinct brain activity linked with cognitive failures (i.e., error commission), and explicit
error awareness [54, 58-60]. Additionally, as the insula’s various cortical and limbic
connections are thought to be involved in a wide range of cognitive [61, 62], motor [63,
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64], and interoceptive [65-68] mechanisms that are vital for everyday functioning, we also
probed insular neurocircuitry by examining whole-brain, resting-state functional
connectivity (rsFC) of three insular subregions.
The insula is also a central node of the salience network (SN), a canonical,
functional brain network involved in monitoring salient stimuli, and deploying attentional
resources to other large-scale networks; the default mode network (DMN) and central
executive network (CEN) [62, 69-71]. The DMN, primarily engaged during intrinsic
thought processes that arise independent of external stimuli [72-74], and the CEN, engaged
during tasks that demand attention and processing external stimuli [75, 76], are accordingly
negatively correlated and the SN is thought to be involved in appropriately toggling
neurocognitive resources between them in an effort to focus attention toward prioritized
information [71, 77, 78]. Thus, we also assessed insular function from a network
perspective by examining interactions between the SN and these two other functional
networks.
As changing laws and societal views continue to provide increased access to CB,
decrease perceptions of harm, and increase use among PLWH, it is critical to understand
the long-term effects CB may have on insula function among PLWH. As such, the main
objective of my dissertation project is to delineate brain processes contributing to certain
HIV-associated cognitive deficits while helping to identify those deficits which are further
impacted by CB. Towards the objective, my dissertation assesses the interactive effects of
HIV and chronic CB use on fMRI measures of insular function and characterizes potential
implications for error processing, everyday functioning, and disease management
behaviors. Specifically, we utilize a cross-sectional, group differences, experimental
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design (co-occurring: HIV+CB+; HIV-only: HIV+/CB; CB-only: HIV-/CB+; controls:
HIV-/CB-) to interrogate separate and interacting effects of HIV and CB at regional, circuit
and network-levels of insula function. My dissertation addresses three main empirical aims
regarding the impact of HIV and CB on (1) task-based insula activity, (2) functional insular
circuitry, and (3) large-scale network interactions.
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CHAPTER 1
Reduced Error-Related Default Mode Network Suppression

1.1. Summary
Brain activity linked with error processing has rarely been examined among persons
living with HIV (PLWH) despite importance for monitoring and modifying behaviors that
could lead to adverse health outcomes (e.g., medication non-adherence, drug use, risky
sexual practices). Given that cannabis (CB) use is prevalent among PLWH and impacts
error processing, we assessed the influence of HIV serostatus and chronic CB use on errorrelated brain activity while also considering associated implications for everyday
functioning and clinically-relevant disease management behaviors. A sample of 109
participants, stratified into four groups by HIV and CB (HIV+/CB+, n=32; HIV+/CB-,
n=27; HIV-/CB+, n=28; HIV-/CB-, n=22), underwent fMRI scanning while completing a
modified Go/NoGo paradigm called the Error Awareness Task (EAT). Participants also
completed a battery of well-validated instruments including a subjective report of everyday
cognitive failures and an objective measure of medication management abilities. Across all
participants, we observed expected error-related anterior insula (aI) activation which
correlated with better task performance (i.e., less errors) and, among HIV- participants,
fewer self-reported cognitive failures. Regarding awareness, greater insula activation as
well as greater posterior cingulate cortex (PCC) deactivation were notably linked with
aware (vs. unaware) errors. Regarding group effects, unlike HIV- participants, PLWH
displayed a lack of error-related deactivation in two default mode network (DMN) regions
(i.e., PCC, medial prefrontal cortex [mPFC]). No CB main or interaction effects were
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detected. Across all participants, reduced error-related PCC deactivation correlated with
reduced medication management abilities and PCC deactivation mediated the effect of HIV
on such abilities. More lifetime CB use was linked with reduced error-related mPFC
deactivation among HIV- participants and poorer medication management across CB
users. These results demonstrate that insufficient error-related DMN suppression linked
with HIV infection, as well as chronic CB use among HIV- participants, has real-world
consequences for medication management behaviors. We speculate that insufficient DMN
suppression may reflect an inability to disengage task irrelevant mental operations,
ultimately hindering error monitoring and behavior modification.

1.2. Introduction
The human immunodeficiency virus (HIV) crosses the blood brain barrier,
replicates, and infects cells in the central nervous system (CNS), leading to
neuroinflammation and neural degeneration [5, 79, 80]. Neuroimaging has identified
structural and functional brain alterations linked with HIV infection, particularly in
frontostriatal circuitry [10-15], that are thought to contribute to a spectrum of progressive
neurocognitive declines characterizing the disease [16-21]. Even with widespread
availability of antiretroviral therapy, approximately 30–50% of persons living with HIV
(PLWH) are impacted by neurocognitive alterations [8, 9]. Accumulating evidence
indicates that PLWH not only exhibit altered neurocognition but also manifest
metacognitive difficulties whereby they under report their cognitive failures when
considered in light of objective behavioral measures [81-84]. Reduced awareness of
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everyday mistakes and errors may impact daily functioning, potentially resulting in
compromised medication adherence and, in turn, disease management.
Highly active antiretroviral therapies (HAART) suppress viral load, improve
cognitive function [85], and prolong life for PLWH [86, 87]. Yet, strict medication
adherence is critical for HAART success [87-90] with even a few days of missed doses
leading to viral load increase [91, 92] and drug resistance [93, 94]. The dosing regimens of
HAART are also complicated, demanding, and challenging to manage; for example, use of
a protease inhibitor requires dosing every 8- or 12 hours and at least two additional
antivirals on potentially different schedules [94]. Cognitive control, attentional, and
psychomotor impairments linked with the infection likely make managing complex
medication regimens even more challenging [94, 95]. Consequently, medication adherence
is a major barrier to sustained health for PLWH [22] and adherence rates are estimated to
only reach 40-67% [96]. Monitoring and recognizing cognitive failures is likely relevant
to medication management as it allows one to rectify errors and adapt behavior thereby
avoiding future negative outcomes.
Given recent changes in societal views, state laws, and clinical practice,
recreational and medical cannabis (CB) use remains prevalent among PLWH [26-28] with
77% reporting lifetime use [29]. Despite anti-inflammatory and other benefits (e.g.,
analgesic, gastrointestinal) potentially linked with CB use by PLWH [28, 33], evidence
suggests chronic use may lead to neurocognitive alterations [40, 43, 47]. Such alterations
appear dependent on CB use histories (e.g., duration, amount [40, 44-46]) and possibly
differ across PLWH and HIV- users [40, 44]. However, given inconsistencies in the
literature, the neuroprotective versus potential adverse synergistic impact of CB use and
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HIV infection remains unclear [47] as does potential consequences for complex real-world
behaviors such as medication management [97, 98].
There is growing appreciation that neurocognitive behavioral measures alone may
not provide a complete perspective on the potential neurobiological impacts of HIV and
CB [47, 48]. Indeed, atypical brain activity among PLWH, measured via functional
magnetic resonance imaging (fMRI) may precede observable declines in cognition and
diagnoses of HIV-associated neurocognitive disorder (HAND) [48]. Although medication
management abilities have been linked with neurocognitive dysfunction among PLWH
[94], altered brain activity underlying and perhaps predating such dysfunction remains to
be characterized. Here, we considered how brain activity linked with cognitive control,
error processing, and error awareness may be altered as both a function of HIV infection
and CB use in the service of enhancing insight into the neurobiological mechanisms
potentially contributing to medication adherence difficulties.
Accumulating neuroimaging evidence implicates both HIV and CB when
considering functional alterations in brain regions contributing to error processing and
awareness. For example, elevated task-related insula activity among PLWH [53] and
reduced error awareness-related insula and dorsal medial prefrontal cortex (dmPFC)
activity among CB users [54] has been documented. Critically, HIV x CB interactive
effects on left anterior insula (aI) activity have been reported in the context of a cognitive
interference fMRI task, such that CB use was associated with increased aI activity among
PLWH, yet decreased activity among HIV- participants [51]. The aI and dmPFC are central
nodes of the salience network (SN), are critically involved in monitoring errors and, more
generally, salient stimuli, as well as the deployment of attentional resources [62, 69-71].
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Regions comprising the SN are also implicated in explicit error awareness [57, 69, 70, 99],
are relevant for optimal task performance [54, 100], and are linked with subjective
awareness of cognitive deficits (i.e., insight) across neuropsychiatric conditions [57, 101,
102]. Another large-scale brain network potentially relevant for optimal cognition is the
default mode network (DMN). The posterior cingulate cortex (PCC) and medial prefrontal
cortex (mPFC) are central DMN nodes [103-105], regions thought to be more active during
task irrelevant mental operations and to deactivate during “task-on” performance [103,
106]. As a robust body of work has shown that trial-by-trial DMN suppression is related to
optimal task performance [107, 108], detection of salient stimuli [109], and increasing
cognitive demands [106, 110], DMN suppression is also likely relevant in the context of
error processing. While insufficient DMN suppression has been implicated in various
neuropsychiatric disorders [62, 111-119], it remains to be considered among PLWH.
As such, we probed brain activity linked with cognitive control (e.g., inhibition),
cognitive failures (i.e., error commission), and explicit error awareness utilizing a
Go/NoGo motor inhibition paradigm called the Error Awareness Task (EAT) among a
participant sample stratified by HIV serostatus and CB use history. We examined the
potential interactive impacts of HIV and CB on brain responsivity to task errors, of which
participants were either aware or unaware. Importantly, we also considered clinicallyrelevant implications by delineating relationships between brain activity and behavioral
measures of cognitive control, error awareness, and medication management ability, as
well as self-reported everyday cognitive failures. We addressed three main empirical
questions involving task-effects, group-effects, and real-world implications. Regarding
task effects, we expected to replicate error-related activity in SN regions and previously
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reported awareness-related brain activations (SN regions) and deactivations (DMN
regions). Regarding group effects, we anticipated observing HIV x CB interactive effects
on EAT-related SN and DMN regional brain activity. Finally, regarding real-world
implications, we expected that error- and/or awareness-related brain activity showing
group differences would be linked with subjectively reported cognitive failures and
objectively measured medication management abilities.

1.3. Methods
Participants. A sample of 109 participants was stratified into four groups on the
basis of HIV serostatus and CB use history (HIV+/CB+, n=32; HIV+/CB-, n=27; HIV/CB+, n=28; HIV-/CB-, n=22). Participants were recruited from community-based
organizations providing health care services throughout Miami-Dade County. All
participants were 18-60 years old to minimize the presence of other chronic conditions
(e.g., hypertension, diabetes), as well as the potential interactive effect of HIV and aging
on neurocognition [120-124]. Additional exclusionary criteria included: current Hepatitis
C infection, English non-fluency or illiteracy, less than an eighth-grade education level,
severe learning disability, serious neurological disorder, severe head trauma with loss of
consciousness >30 min, severe mental illness with psychotic or paranoid symptoms, or
MRI contraindications. All PLWH in the study were taking antiretroviral medications,
were diagnosed with HIV 9.8±9.2 (mean±SD) years prior to assessment, and had no history
of opportunistic infections affecting the CNS. All CB using participants reported a history
of regular use (at least once per week for three straight weeks) and used at least 20 times
in the past year. The CB- participants met the following criteria: no CB use in the past 12
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months, and a negative urine THC screen. Past use of and dependence on other substances,
including alcohol, nicotine, cocaine, amphetamines, benzodiazepines, or opioids was
permitted across each group to provide a more representative and generalizable sample.
However, participants were excluded if meeting criteria for current substance dependence
(except nicotine and CB) as assessed via the DSM-5 Structured Clinical Interview [125].
Procedures. Study procedures were reviewed and approved by FIU’s Institutional
Review Board. Following informed consent, we collected blood, behavioral, self-report,
and MRI data across two study visits on different days. The CB+ participants were
instructed to refrain from use for 24 hours before study visits to minimize acute
pharmacological and/or withdrawal-related effects. Upon arrival at both visits, participants
completed substance use screening including urine toxicology (Drug Check Cup, NXStep)
and breathalyzer testing (AlcoMate Premium Breathalyzer). During the first visit, blood
specimens were collected and participants completed a battery of behavioral tests and selfreport questionnaires. Among PLWH, blood samples were used to quantify HIV disease
severity (HIV-1 viral load) and immune function (lymphocyte T-cell subset counts).
Among CB+ participants, samples were used to quantify cannabinoid levels (plasma 9carboxy-THC and THC to creatine ratios). The second visit occurred within 1 month after
the first and participants completed a 1-hour MRI scan after task training and completion
of additional self-reports. Participants were compensated at the end of each visit.
Behavioral and self-report measures. Participants completed a battery of wellvalidated behavioral and self-report instruments. Herein, we focus on measures pertaining
to self-reported cognitive failures, medication management abilities, and detailed CB use
history. To quantify self-awareness of everyday cognitive failures, we considered
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participants’ total scores on the Cognitive Failures Questionnaire (CFQ) [126]. The CFQ
is a 25-item questionnaire assessing the occurrence of absent-mindedness or slips of
perception, memory, and motor functioning. Among healthy participants, CFQ total scores
are linked with inattentiveness, forgetfulness, and/or accidents in both the laboratory and
real-world resulting from distractibility, poor selective attention, or other mental errors
[127]. To quantify medication management abilities, participants completed the Revised
Medication Management Test (MMT-R), a 10-minute behavioral test validated for use
among PLWH [128]. The MMT-R assesses an individual’s ability to accurately follow a
fictitious prescription regimen and answer questions about the mock medications [129,
130]. The MMT-R involves a pill dispensing component designed to emulate the complex,
multi-medicine regimens currently used for HIV treatment and a medication inference
component [130]. During the pill dispensing component, participants transferred mock
pills from bottles to a 1-week pill organizer. To quantify CB use history, self-reported
information on frequency, amount, and duration of CB (and other drug) use was collected
via selected items from the National Survey on Drug Use and Health [131].
Error Awareness Task (EAT). During MRI scanning, participants completed a
modified Go/NoGo motor inhibition paradigm called the Error Awareness Task (EAT) [54,
58-60]. In the EAT, participants commit errors (i.e., incorrectly press a button following a
NoGo cue) of which they can be either aware or unaware. Participants indicate error
awareness by pressing an error signaling button. The EAT allows for assessment of distinct
brain activity linked with cognitive control (e.g., inhibition), cognitive failures (i.e., error
commission), and explicit error awareness.
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During the task, participants viewed a series of color words (e.g., “RED”) presented
one at a time which were written in a font/ink color that was either congruent with the
word’s meaning (e.g., the word “RED” written in red font) or incongruent (e.g., “RED” in
blue font). Words were initially displayed for 900ms followed by a 600ms inter-stimulus
interval. Participants were instructed to press button-1 on a two-button response box
(Current Designs, Philadelphia, PA) as quickly as possible during the stimulus display
window each time a new word appeared (Go trials). Participants were instructed to
withhold this button press under two conditions (NoGo trials). The first NoGo condition
was when the same congruent word-ink stimulus was repeated on two consecutive trials
(NoGo: repeat). The second was when the word’s meaning and ink color were incongruent
(NoGo: Stroop). Go trials occurred more frequently than NoGo trials (5:1 ratio) to render
a Go button press a prepotent response. An equal number of NoGo: repeat and NoGo:
Stroop trials were pseudo-randomly presented across the task, such that there were at least
3 and at most 7 Go trials between each NoGo cue. The two NoGo conditions were included
to increase task difficulty and ensure a sufficient number of errors [58]. Specifically, given
the overlearned human tendency to read words relative to identifying the font color,
participants were expected to more successfully monitor for the NoGo: repeat condition
leading to fewer errors relative to the NoGo: Stroop condition. To indicate explicit
awareness following commission errors, participants were trained to press an error
signaling button (button-2) on the Go trial immediately following the erroneous response
(hereafter referred to as the awareness trial). Successful inhibition in the EAT necessitates
decision-making and multiple cognitive control processes. Specifically, identification of
NoGo: repeat trials requires working memory maintenance of the preceding word whereas
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identification of NoGo: Stroop trials involves cognitive interference from the prepotent
word reading response [58, 132]. Consequently, successful inhibition necessitates the
execution of multiple, confounded, cognitive control processes including: sustained
attention for monitoring stimuli, successful NoGo stimulus detection, and ultimately motor
inhibition of the prepotent Go response. Thus, we considered successful motor inhibition
as the culmination of a series of successful goal-directed cognitive control processes (as
opposed to isolation of the response inhibition construct) and error commission as a general
cognitive failure.
Participants completed EAT training and then performed a 5.5min practice run in a
mock scanner. During MRI scanning, participants completed six, 5.5min task runs
involving a total of 1,296 trials (1,080 Go trials, 216 NoGo trials [NoGo: repeat, n=108;
NoGo: Stroop, n=108]) with short rest periods (~30sec) between runs 1-2, 3-4, and 5-6 and
longer breaks between runs 2-3 (6min for a structural MRI scan) and runs 4-5 (8min for a
resting-state fMRI scan). To achieve sufficient numbers of successful and unsuccessful
NoGo trials, task difficulty was individually and dynamically adapted to maintain
participants’ average NoGo error rate between 45-50%. Specifically, after the first 40 trials,
when a participant’s average NoGo error rate fell below 45%, the length of the response
window (initially 900ms) was reduced by 250ms (minimum allowable: 500ms).
Alternatively, when the average NoGo error rate rose above 50%, the response window
increased by 250ms (maximum allowable: 1000ms).
EAT behavioral measures: Statistical analyses. Behavioral variables of interest
included the: a) number of Go trials with a correct (Go-correct) or missed response (Goerror [omission]), b) number of successfully (NoGo-correct) and unsuccessfully inhibited
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NoGo trials (NoGo-error), and c) number of NoGo-errors for which participants indicated
error awareness (NoGo-error: Aware), failed to indicate awareness (NoGo-error:
Unaware), or did not respond on the awareness trial (NoGo-error: No response). Regarding
response times (RTs), variables of interest included: average RT on Go trials immediately
preceding (pre-error) and following (1-post-error) aware and unaware NoGo-errors. Given
that the 1-post-error trial (i.e., the awareness trial) was confounded with the additional error
signaling process, we also considered RTs on the subsequent Go trial (2-post-error). As the
EAT’s difficulty manipulation was intended to maintain error rates at ~45-50%, we did not
anticipate between-group differences on this variable. However, we aimed to replicate prior
reports of higher error rates for NoGo: Stroop versus NoGo: repeat trials (e.g., [54, 59]).
As such, we performed a 3-way, 2(HIV: + vs. -) x 2(CB: + vs. -) x 2(NOGO-TYPE: Stroop
vs. repeat) mixed-effects ANOVA focusing on the NOGO-TYPE main effect. To assess
potential between-group differences in error awareness, we performed a similar 3-way
ANOVA (2[HIV] x 2[CB] x 2[AWARENESS: aware vs. unaware]). To characterize RT
patterns following aware and unaware errors (i.e., post-error speeding or slowing), we
performed a 4-way, 2(HIV) x 2(CB) x 2(AWARENESS) x 3(TRIAL: pre- vs. 1-post- vs.
2-post-error) mixed-effects ANOVA. We focused on the AWARENESS x TRIAL
interaction as we aimed to replicate RT reductions following aware (post-error speeding),
but not unaware errors [58]. Behavioral data were analyzed with SPSS (v.26) and Python
(2.7.10).
MRI data acquisition and analysis. MRI data were collected on a GE Healthcare
Signa MR750, 3-Tesla scanner with 32-channel head coil. For the six functional EAT runs,
42 slices (3.4mm thick) were obtained in the axial plane using a T2*-weighted, single-shot,
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gradient-echo, echo-planar imaging (EPI) sequence sensitive to blood oxygenation level–
dependent (BOLD) effects (169 volumes/run, repetition time [TR]=2000ms, echo time
[TE]=30ms, flip angle [FA]=75°, field of view=220mm, 64x64 matrix, voxel size = 3.44 x
3.44 x 3.40 mm3). These same EPI parameters were used to collect an 8min resting-state
scan with eyes closed (245 volumes, data not reported herein). T1-weighted structural
images were obtained using a magnetization-prepared rapid gradient-echo (MPRAGE)
sequence (TR=2500ms; TE=3.7ms; FA=12°; voxel size=1mm3).
MRI data preprocessing was performed with FMRIPREP v1.1.1 [133], a Nipypebased tool [134] often employing Nilearn [135]. T1-weighted structural volumes were
corrected for intensity non-uniformity (N4BiasFieldCorrection v2.1.0) [136] and skullstripped (antsBrainExtraction.sh v2.1.0). Nonlinear registration (ANTs v2.1.0) was
performed to normalize T1-weighted volumes to the ICBM-152 asymmetrical template
v2009c [137]. Functional data were motion corrected using MCFLIRT (FSL v5.0.9) [138]
and slice-time corrected to the middle of each TR using 3dTshift (AFNI v16.2.07) [139].
Distortion correction was performed by co-registering functional images to corresponding,
intensity inverted [140, 141] anatomical volumes constrained by an average field map
template [142]. Functional images were then co-registered to corresponding T1-weighted
volumes using boundary-based registration [143] with 9 degrees of freedom via bbregister
(FreeSurfer v6.0.1). The motion correction transformations, distortion correction warp,
functional-to-anatomical transformation, and anatomical-to-template warp were all
concatenated

and

applied

in

a

single

(antsApplyTransforms ANTs v2.1.0).
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step

using
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Subject-
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in

AFNI

(http://afni.nimh.nih.gov/afni/). Following preprocessing, the six EAT runs were smoothed
to 8mm FWHM (3dBlurToFWHM) and time series were scaled to the voxel-wise mean
(3dcalc) thereby allowing regression (β) coefficients, calculated per regressor and
participant, to be interpreted as an approximation of percent BOLD signal change (%
BOLD Δ) [144] from the implicit baseline. The first five functional volumes of each run
and those with framewise displacement greater than 0.35mm were censored (1.2±3.9% of
TRs). Groups did not differ in the number of censored TRs (HIV: F[1, 105]=0.6, p=0.4;
CB: F[1, 105]=1.9, p=0.2; HIVxCB: F[1, 105]=0.7, p=0.4). Functional data were then
entered into two separate subject-level general linear models (GLMs) including taskrelated and nuisance regressors (i.e., six motion-correction parameters and fourth-order
polynomials capturing residual head motion and baseline trends in the BOLD signal,
respectively). To characterize brain activity linked with cognitive control/failures, the
first GLM included three task-related regressors (NoGo-correct [C], NoGo-error [E], and
Go-error [O, omission]) as impulse functions time-locked to stimulus onset and convolved
with a hemodynamic response (gamma) function. To characterize brain activity linked with
error awareness, the second GLM included the same nuisance regressors and now four
task-related regressors again including NoGo-correct [C] and Go-error [O] regressors, but
here, NoGo-errors [E] were parsed into two types, 1) NoGo-error: Aware [A], and 2)
NoGo-error: Unaware [U].
EAT-related brain activity: Task effects. Task- and group-effect statistical tests
were conducted within a sample-specific whole-brain mask that included those voxels in
which ≥80% of participants’ functional runs had a non-zero value. The overlap mask’s
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perimeter was eroded by one voxel yielding a final mask with 41,726 voxels. To
characterize cognitive control/failure-related activity, NoGo-correct minus NoGo-error
[C-E] contrast values were assessed across a sample of 103 participants demonstrating
sufficient task engagement (i.e., responded to >50% of Go trials) with a whole-brain, onesample t-test (two-tailed, 3dTtest++). For visualization, the resulting maps were
thresholded at pvoxel-wise=1.0e-10, cluster extent: 20 voxels (arbitrarily chosen). To assess
error awareness-related activity, a whole-brain, one-sample t-test on NoGo-error: Aware
minus NoGo-error: Unaware [A-U] contrast values was conducted across a sample of 86
participants demonstrating sufficient trial numbers (i.e., committed ≥2 aware and ≥2
unaware NoGo-errors) (pFWE-corrected <0.05; pvoxel-wise<0.0001, cluster extent: 7 voxels,
3dClustSim with spatial autocorrelation correction [145]).
For graphical examination and follow-up analyses, we extracted the average β
coefficients associated with specific task events ([C], [E], [A], [U]) and contrasts ([C-E],
[A-U]) by averaging across all non-zero voxels within clusters/regions of interest (ROIs)
identified via the cognitive control/failure and error awareness statistical maps. To
assess brain-behavior relationships, we considered the total number of NoGo-errors
(ERROR COUNT) as an objective, laboratory-based measure of cognitive failures and the
total scores on the CFQ (CFQ) as a subjective measure of real-world cognitive failures. We
also considered the percent of unaware NoGo-errors (% UNAWARE) as an objective
measure of error awareness. First, we performed bivariate Pearson’s correlations between
the average cognitive control/failure error-specific β coefficients [E] and ERROR
COUNT. These analyses were Bonferronni-corrected for the n=4 ROIs considered.
Regarding error awareness-related activity, we performed correlations between [A-U]
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contrast values and % UNAWARE (Bonferronni-corrected, n=4). As the % UNAWARE
distribution was right-skewed, this variable was log10 transformed. Additionally, we
conducted exploratory analyses examining whether HIV serostatus moderated the
relationship between self-reported cognitive failures (CFQ) and behavioral performance
(ERROR COUNT, % UNAWARE) or task-related brain activity (error [E] β coefficients,
[A-U] contrast values) by conducting separate HIV x CFQ ANCOVAs. As these analyses
were exploratory, we did not apply multiple comparison corrections.
EAT-related brain activity: Group effects. Group differences in cognitivecontrol/failure [C-E] and error awareness [A-U] activity were assessed via whole-brain,
2(HIV) x 2(CB) ANOVAs (3dMVM). HIV and CB main and interaction effects were of
interest (pFWE-corrected<0.05; pvoxel-wise<0.001, cluster extent: 35 voxels). These group-effects
analyses were also performed using sex, age, and IQ as covariates. No significant covariate
influences were detected; thus, results from the initial analyses are reported. The β
coefficients and contrast values from identified ROIs were extracted for graphical
examination and follow-up analyses. We assessed whether HIV serostatus moderated the
relationship between behavioral performance (ERROR COUNT) and task-related brain
activity (error [E] β coefficients) by conducting HIV x ERROR COUNT ANCOVAs
(Bonferroni-corrected for n=2 ROIs considered).
To fully characterize group differences in brain activity across various trials, we
computed β coefficients for the three Go trials both preceding (3-pre, 2-pre, 1-pre) and
following a NoGo-error (1-post [awareness trial], 2-post, 3-post). Specifically, we
performed six separate GLMs similar to that described above when considering cognitive
control/failures, except in these GLMs, the NoGo-error [E] regressor was replaced with
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one modeling a specific error-preceding or error-succeeding Go trial. Average β
coefficients were extracted from ROIs and plotted with respect to NoGo-error [E] and
NoGo-correct [C] activity for qualitative inspection and exploratory analyses. We
performed a 2(HIV) x 6(TRIAL: 3-pre vs. 2-pre vs. 1-pre vs. 1-post vs. 2-post vs. 3-post)
mixed-effects ANOVA on each ROI’s β coefficients with a focus on the HIV x TRIAL
interaction (Bonferroni-corrected for n=2 ROIs).
To probe clinically-relevant implications of HIV-associated alterations, we
examined relationships between error-related brain activity, behavioral performance on the
MMT-R (MMT SCORE), and self-reported CFQ total scores (CFQ). Specifically, we
conducted HIV x MMT SCORE and HIV x CFQ ANCOVAs when considering NoGoerror activity [E] extracted from those ROIs demonstrating group effects above. Follow-up
conditional effects within groups were assessed using the PROCESS v.5 SPSS plugin
[146]. Finally, we tested a mediation model (corresponding to Model 4 in Hayes, 2017
[146]) in which error-related brain activity (M) mediated the effect of HIV serostatus (X)
on MMT SCORE (Y). While the cross-sectional and observational nature of our research
design limits conclusions about causality, we aimed to provide a descriptive (as opposed
to predictive) account of hypothesized co-relations between these variables [146, 147].
Finally, to evaluate the impact of self-reported lifetime CB use (LIFETIME AMOUNT)
among HIV+ and HIV- CB using participants (n=55), we assessed HIV x LIFETIME
AMOUNT interactions (controlling for past month nicotine use) on task-related brain
activity (error [E] β coefficients), MMT SCORE, and CFQ.
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1.4. Results
EAT behavioral measures. Six participants (n=2 HIV+/CB+, n=2 HIV+/CB-, n=2
HIV-/CB+, n=0 HIV-/CB-) with more than 50% Go-errors (i.e., omissions) were excluded
from subsequent behavioral and neuroimaging analyses. The remaining 103 participants,
failed to respond on 3.1±0.6% (mean±SEM) of Go trials and failed to withhold a button
press response on 46.1±1.5% of NoGo trials (Table 2). Given the dynamic task-difficulty
manipulation, we did not observe any significant group effects when considering NoGoerrors in a 2(HIV) x 2(CB) x 2(NOGO-TYPE: Stroop vs. repeat) ANOVA (p’s>0.4).
However, a NOGO-TYPE main effect was detected (F[1,99]=85.5, p<0.001) such that
more errors were committed on Stroop (59.1±1.0% of NoGo-errors) versus repeat trials
(40.9±1.0%, Table 2, Fig. 1A), consistent with previous reports (e.g. [54, 59]) and the
interpretation that the NoGo: Stroop rule was more difficult to monitor [58].
Also consistent with prior task implementations [54, 58-60], participants were
aware of most errors (73.4±2.4%), were unaware of 21.2±2.3%, and failed to respond after
5.4±0.7% of errors (Table 2, Fig. 1A). To assess group differences in error awareness, we
performed a 2(HIV) x 2(CB) x 2(AWARENESS: aware vs. unaware) ANOVA. While we
detected an AWARENESS main effect (F[1, 99]=106.5, p<0.001) indicating that
participants were aware of most errors, we did not observe any significant group-related
main effects or interactions (p’s>0.9). Consistent with previous reports [54, 58, 59],
participants failed to indicate awareness more often following repeat (28.6±2.8%) versus
Stroop trials (15.5±2.1%; t[102]=7.7, p<0.001; Fig. 1A).
For awareness-related brain and behavioral assessments, only participants with at
least two instances of aware and unaware errors were considered. Three participants (n=1
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HIV+/CB+; n=1 HIV+/CB-; n=0 HIV-/CB+; n=1 HIV-/CB-) were excluded from further
analyses as they indicated awareness of too few errors, suggesting that they did not
understand the error awareness signaling procedure. Another 14 participants (n=8
HIV+/CB+; n=3 HIV+/CB-; n=1 HIV-/CB+; n=2 HIV-/CB-) were excluded as they had
too few unaware trials (i.e., they detected all errors). This yielded a sample of 86
participants available for error awareness assessments.
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Table 1. Demographic and drug use characteristics: Sample with task-based data.
All
Participants
n=109

HIV+/CB+

HIV+/CB-

HIV-/CB+

HIV-/CB-

n=32

n=27

n=28

n=22

Group Effects (p’s)
HIVxCB

HIV

CB

Demographic
Age

35.8 (10.7)

34.8 (9.2)

37.0 (12.7)

34.9 (11.4)

37.2 (9.7)

0.9

0.9

0.3

Education (years)

13.8 (2.3)

13.8 (2.3)

13.7 (2.7)

13.7 (2.6)

13.9 (1.7)

0.7

0.9

0.9

IQ

101.23 (10.7)

100.9 (10.0)

98.9 (11.4)

101.4 (11.3)

104.4 (9.9)

0.2

0.1

0.8

male, female

74, 35

29, 3

18, 9

16, 12

11, 11

-

0.004

0.1

AA, C, >1

53, 50, 5

15, 17, 0

13, 12, 2

15, 11, 2

10, 10, 1

-

0.7

0.8

Hispanic/Latinx

45

14

11

9

11

-

0.8

0.5

19.6 (6.7)

20.9 (6.6)

-

18.1 (6.6)

-

-

0.6☨

-

☨

Cannabis use
Age regular use
Years regular use

16.9 (9.8)

16.3 (9.6)

-

17.6 (10.1)

-

-

0.1

-

Past month(times)

13.0 (14.0)

21.9 (10.7)

0

25.6 (9.2)

0

0.2

0.2

<0.001

Lifetime (times)

2,405 (3,357)

3,766 (3,489)

114 (428)

4,580 (3,733)

468 (1,423)

0.7

0.3

<0.001

Other drug use (past month, times)
Alcohol

2.3 (3.6)

2.2 (2.7)

2.1 (4.1)

3.3 (4.6)

1.6 (2.7)

0.2

0.7

0.2

Cocaine
Nicotine

0.0 (0.1)
5.5 (11.3)

0.1 (0.2)

0

0

0

0.2

0.2

0.2

8.2 (13.3)

0.3 (1.5)

7.9 (13.1)

4.9 (10.8)

0.3

0.3

0.012

NOTE. Data are either expressed as mean (standard deviation) or frequency across all participants or specific groups. Drug use is
self-reported number of times using each drug in the given timeframe (past month, lifetime). Group effects were assessed via either
an HIV x CB ANOVA or, for categorical variables, via Chi-square tests (one comparing HIV+ vs. HIV- groups and one comparing
CB+ vs. CB- groups). IQ: estimate of premorbid function based on the Wechsler Test of Adult Reading (WTAR) [148]. AA: African
American, C: Caucasian, A: Asian, >1: more than one race., ☨independent samples t-test between CB+ groups.
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To assess RT patterns following (un)aware errors, we performed a 2(HIV) x 2(CB)
x 2(AWARENESS) x 3(TRIAL: pre- vs. 1-post- vs. 2-post-error) mixed-effects ANOVA.
While no group-related effects were observed, an AWARENESS x TRIAL interaction was
detected (F[2, 81]=53.1, p<0.001; Fig. 1B). Follow-up tests identified a main effect of
TRIAL when considering RTs associated with both aware (F[2,170]=14.4, p<0.001) and
unaware errors (F[2,170]=15.1, p<0.001). These main effects were driven by two distinct
post-error (vs. pre-error) RT patterns. Specifically, RTs were faster on the Go trial
immediately following (vs. preceding) an aware error (1-post-error: t[85]=4.2, p<0.001),
yet RTs were slower following an unaware error (1-post-error: t[85]=-4.4, p<0.001). As
RTs on the first post-error trial (i.e., the awareness trial) were confounded with the error
signaling process, we also considered RTs on the subsequent Go trial (2-post-error). We
again observed faster RTs (speeding-up) following aware errors (2-post-error: t[85]=9.5,
p<0.001), but detected no such RT difference following unaware errors (t[85]=-1.8,
p=0.07). The post-error speeding after aware, yet post-error slowing after unaware errors,
is consistent with prior EAT findings [58]. We speculate that these RT patterns reflect an
‘eagerness’ to indicate error awareness following aware errors that is not present after
unaware errors.
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Figure 1. EAT behavioral performance measures. (A) Participants indicated awareness
of most errors (aqua: 73.4±2.4%) and were more likely to be aware of Stroop errors
(79.3±2.3%) relative to repeat errors (65.6±2.8%; t[102]=7.7, p<0.001). Participants were
unaware (blue) of 21.2% of errors and had a similar percent of no responses following
Stroop (gray: 5.2%) and repeat errors (gray: 5.8%; t[102]=-0.7, p=0.5). (B) When
considering aware errors, RTs were faster on the first (356±19ms) and second post-error
Go trials (364±11ms) relative to the pre-error Go trial (444±7ms; F[2,170]=14.4, p<0.001).
In contrast, for unaware errors, RTs were slower on the first post-error Go trial (523±12ms)
and did not differ for the second post-error trial (462±9ms) relative to pre-error RTs
(448±9ms; F[2, 170]=15.1, p<0.001).
Table 2. EAT behavioral performance measures.

a)

b)

c)

d)

Trial Type

Mean ± SEM

Range

% Go-correct

96.9 ± 5.8

65.3 - 100

% Go-error (omission)

3.1 ± 0.6

0 - 34.7

% NoGo-correct

53.9 ± 1.5

13.4 - 91.7

% NoGo-error (commission)

46.1 ± 1.5

8.3 - 86.6

% NoGo-error: Aware

73.4 ± 2.4

0 - 100

% NoGo-error: Unaware

21.2 ± 2.3

0 - 100

% NoGo-error: No response

5.4 ± 0.7

0 - 33.5

% NoGo-error: Repeat
% NoGo-error: Stroop

40.9 ± 1.0
59.1 ± 1.0

19.8 - 74.6
25.4 - 80.2
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NOTE. Values in section a) are expressed as the percentage of trials out of all Go trials.
Values in section b) are expressed as the percentage of trials out of all NoGo trials. Values
in sections c) and d) are expressed as the percentage of trials out of all NoGo-errors. Values
in each section (a-d) sum to 100%. SEM: standard error of the mean. See Supplemental
Table S6 for all EAT trial type counts and percentages.
Task effects: Cognitive control/failure-related brain activity. To characterize
activity differences during cognitive control failures (errors) versus successes (inhibitions),
we contrasted BOLD signal changes associated with NoGo-error [E] versus NoGo-correct
trials [C] (Fig. 2A). Increased activity during error trials [E>C] was observed notably in
the bilateral aI, dmPFC (Fig. 2B), thalamus, and a large cluster encompassing the left
primary and supplementary motor areas. In contrast, during correct trials [C>E], increased
activity was observed in bilateral dorsal medial parietal cortex (dmPC), the bilateral
putamen extending into the nucleus accumbens, the bilateral hippocampi, and the occipital
lobe. We then assessed relations between error-related brain activity and the number of
NoGo-errors committed (ERROR COUNT), an objective laboratory-based measure of
cognitive failures. Increased error-related activity in the left aI (r[101]=-0.3, p=0.02) and
decreased error-related activity in the dmPC (r[101]=0.4, p<0.004; Fig. 2C) correlated
with fewer errors. We also considered brain-behavior relationships focusing on CFQ total
scores, a self-reported measure of real-world cognitive failures (Fig. 2D). HIV serostatus
moderated the association between self-reported cognitive failures and error-related left aI
(HIVxCFQ: F[1,99]=4.0, p=0.049) and dmPFC activity (F[1,99]=9.1, p=0.003). Followup examination of within-group conditional effects indicated that among HIV- participants
more error-related activity in the left aI (β=-0.02, p=0.02) and dmPFC (β=-0.02, p=0.03)
was linked with fewer self-reported cognitive failures. Different patterns were observed
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among PLWH such that error-related aI activity was not correlated with self-reported
cognitive failures (β=0.003, p=0.7) and less dmPFC activity was related to fewer cognitive
failures (β=0.01, p=0.04).

Figure 2. Whole-brain activity following error [E] and correct [C] NoGo trials. A)
Across the sample of 103 participants demonstrating sufficient task engagement (i.e.,
responded to >50% of Go trials), cognitive control failures (errors) were associated with
increased activity in the bilateral anterior insula (aI), dorsal medial prefrontal cortex
(dmPFC), left thalamus, and left primary motor cortex extending into supplementary motor
regions (warm colors, E>C). On the other hand, cognitive control successes (inhibitions)
were associated with increased activity in the bilateral putamen and dorsal medial parietal
cortex (dmPC; cold colors, C>E; pcorrected<1.0e-10). B) Mean percent BOLD signal change
(β) values for NoGo-error and -correct trials from the (1) left aI, (2) dmPFC, and (3) right
dmPC (numbering corresponds to that shown in panel A). C) Correlations between errorrelated β values from each ROI and an objective measure of cognitive failures. More errorrelated left aI activity (pBonferronni-corrected=0.02) and more right (pBonferronni-corrected<0.004) and
left dmPC activity [r(101)=0.4, pBonferronni-corrected<0.004, data not shown] correlated with
fewer NoGo errors. D) Significant HIV x CFQ interactions were detected when considering
error-related left aI (p=0.049) and dmPFC activity (p=0.003) such that more activity was
linked with less self-reported cognitive failures among HIV- participants (green), but not
among HIV+ participants (purple). See Supplemental Table S7 for cluster coordinates.
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Task effects: Error awareness-related brain activity. To characterize activity linked
with explicit error awareness, we contrasted BOLD signal changes associated with Aware
[A] versus Unaware [U] NoGo-errors (Fig. 3A). Increased activity during aware error trials
[A>U] was observed notably in the bilateral insulae, the bilateral putamen (Fig. 3B), the
posterior thalamus, and in bilateral clusters extending into the dmPFC, and encompassing
the primary and supplementary motor areas. In contrast, during unaware errors [U>A], we
observed increased activity in a right mPFC cluster and reduced deactivation in the bilateral
PCC (Fig. 3B). We then assessed relationships between awareness-related brain activity
([A-U] contrast values) and the percent of unaware errors (% UNWARE), an objective
measure of explicit error awareness. Increased awareness-related brain activity in the right
putamen was associated with reduced awareness behavioral performance, although this
association failed to reach significance following multiple comparisons correction
(r[84]=0.3, p=0.07; Fig. 3C). When considering brain-behavior relationships focusing on
CFQ scores (Fig. 3D), HIV did not moderate the relationship between awareness-related
brain activity and self-reported cognitive failures. Rather, we observed a main effect of
CFQ in the left PCC (F[1, 82]=4.3, p=0.04) such that, across both PLWH and HIVparticipants, more deactivation following aware (vs. unaware) errors correlated with fewer
self-reported cognitive failures. We did not observe any relationships between CFQ and %
UNAWARE (p’s>0.09). At the whole-brain level, no group effects were detected when
considering the [A-U] contrast images. However, follow-up exploratory analyses assessing
group effects on averaged NoGo-error-aware [A] and NoGo-error-unaware [U] β
coefficients within selected ROIs are reported in the supplemental material (Supplemental
Figure S3).

29

Figure 3. Whole-brain activity following aware [A] and unaware [U] errors. A) Across
the sample of 86 participants committing a sufficient number of aware and unaware errors,
explicit error awareness was associated with increased activity in the bilateral insula,
bilateral putamen, posterior thalamus, and bilateral primary motor cortex extending into
supplementary motor regions (warm colors: A>U, pcorrected<0.05). On the other hand,
unaware error trials were associated with increased activity (i.e., less deactivation) of the
bilateral posterior cingulate cortex (PCC) (cold colors: U>A). B) Mean percent BOLD
signal change (β) values for aware and unaware error trials for the (1) right insula, (2) right
putamen, and (3) left PCC. C) Correlations between the percent of unaware errors and [AU] contrast values from each ROI. More aware (vs. unaware) error-related brain activity in
the right putamen correlated with a higher percentage of unaware errors, but this
association did not survive multiple comparison corrections (pBonferronni-corrected =0.07). D) A
main effect of CFQ total scores on left PCC (p=0.04) awareness-related activity was
detected such that across all participants, more PCC deactivation following aware (vs.
unaware) errors was linked with fewer self-reported cognitive failures. See Supplemental
Table S8 for cluster coordinates.
Group effects: Cognitive control/failure-related brain activity. To delineate
functional brain alterations as a function of HIV and CB, we assessed [E-C] contrast images
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in a whole-brain ANOVA. While we did not detect any clusters displaying HIV x CB or
CB main effects, we did observe HIV main effects in the PCC and mPFC (Fig. 4A).
Graphical assessment of β values extracted from these ROIs indicated that HIV+ (vs. HIV) participants displayed less regional deactivation following errors, but not correct trials
(Fig 4B). To further characterize PCC and mPFC activity dynamics across EAT trials, we
conducted qualitative inspection and follow-up assessments when considering β
coefficients for the three Go trials both preceding (1-pre, 2-pre, and 3-pre) and succeeding
a NoGo-error (1-post [awareness trial], 2-post, 3-post) (Fig. 4C). Both the PCC
(F[5,505]=4.1, p=0.03) and mPFC (F[5,505]=6.6, p=0.002) displayed a significant
HIVxTRIAL interaction such that HIV- participants displayed deactivation on the Go trials
immediately preceding NoGo-errors (1-pre), displayed the most deactivation on error
trials, and this deactivation persisted into the next trial (1-post/awareness trial). In contrast,
PLWH maintained relatively stable PCC and mPFC activity across trial types. As the two
groups displayed large activity differences on error trials, we assessed the relation between
error-related PCC and mPFC deactivations and cognitive control performance (i.e., NoGoerror count; Fig. 4D). Among HIV- participants, more error-related PCC deactivation was
linked with fewer errors (p=0.048), whereas among PLWH the opposite pattern was
observed such that more PCC deactivation was linked with more errors (p=0.049).
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Figure 4. HIV+ vs. HIV- group differences in error-related brain activity. A) HIV
main effects were observed in the posterior cingulate cortex (PCC, 39 voxels) and medial
prefrontal cortex (mPFC, 36 voxels; whole-brain HIV x CB ANOVA, pcorrected<0.05) when
considering NoGo correct vs. error [C-E] contrast values. B) Qualitative inspection of
BOLD signal change within identified ROIs indicated that, during errors (red bars), the
HIV- (vs. HIV+) group displayed more deactivation in the PCC (1) and mPFC (2). C) β
coefficients during NoGo-errors, and the three Go trials both preceding (1-pre, 2-pre, and
3-pre) and following a NoGo-error (1-post [awareness trial], 2-post, 3-post) plotted
sequentially with respect to NoGo-correct β coefficients for comparison. We detected HIV
x TRIAL interactions for the PCC (pBonferronni-corrected=0.03) and mPFC ROIs (pBonferronnicorrected=0.002; NoGo-error and NoGo-correct β coefficients were not included in this
statistical test to avoid circular analyses). Qualitative inspection indicated that both PCC
and mPFC activity among HIV- participants displayed a deactivation the trial before an
error, showed the most deactivation following errors, and that this deactivation persisted
into the next trial. In contrast, PLWH showed relatively little modulation of ROI activity
across the various trials (*’s indicate significant difference between HIV groups in followup t-tests). D) Significant HIV x ERROR COUNT interactions on error-related PCC [E] β
coefficients (F[1,99]=6.0, pBonferronni-corrected =0.01). Among HIV- participants, more PCC
deactivation following errors correlated with fewer NoGo errors, whereas among PLWH
the opposite pattern was observed. See Supplemental Table S9 for cluster coordinates.
Real-world implications: Error-related PCC deactivations correlated with
medication management ability. When controlling for biological sex and lifetime CB use,
PLWH displayed poorer MMT performance (10.8±0.5) relative to HIV- participants
(11.9±0.4; F[1,97]=8.0, p=0.006). However, self-reported cognitive failures (CFQ total
scores) did not differ between HIV groups (F[1,97]=0.4, p=0.5) and no correlation between
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MMT performance and CFQ scores was detected (r[101]=-0.04, p=0.7). We then
considered brain-behavior relationships focusing on MMT performance. We observed that
error-related PCC deactivations were associated with MMT performance (F[1,99]=11.4,
p=0.001; Fig. 5A) such that enhanced deactivation was linked with better medication
management across both HIV groups (HIVxMMT: F[1,99]=0.2, p=0.9). Next, we formally
tested the relationship between these variables in a mediation model. PCC deactivation (M)
mediated the effect of HIV serostatus (X) on medication management (Y; CI95% = -0.05,
-0.06; Fig. 5B) such that PLWH displayed reduced error-related PCC deactivation
(p<0.001) which, in turn, was associated with poorer MMT performance (p<0.001).
Pathways remained unchanged when including sex and lifetime CB use as covariates.
Given limitations of the cross-sectional and observational nature of our study design, we
do not assume causality between these variables [146, 147]. We did not detect any
significant relationships between error-related ROI activity and self-reported cognitive
failures (p’s>0.3; Fig 5C).

Figure 5. Relations between error-related brain activity and medication management.
A) Greater error-related PCC deactivation was linked with better MMT performance
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(ANCOVA, MMT main effect: p=0.001) among both HIV+ (p=0.01) and HIV- (p=0.03)
individuals. B) Error-related PCC activity (M) mediated (CI95%=0.01, 0.14) the
relationship between HIV-status (X) and MMT scores (Y) such that, the HIV+ group had
reduced PCC deactivation which was associated with poorer MMT performance. The
mediation model was not significant for mPFC error activity (CI95%= -0.01, 0.10). C)
Error-related PCC and mPFC activity was not correlated with self-reported cognitive
failures (CFQ total scores, p’s>0.3).
Impact of chronic CB use on brain and behavior. While we did not detect
differences among CB using groups when considering error-related PCC or mPFC activity
(p’s>0.8), we observed that lifetime CB use impacted the magnitude of mPFC
deactivations among HIV- participants, but not among PLWH. Specifically, when
controlling for past month nicotine use, we observed a significant HIV x LIFETIME
AMOUNT interaction when considering mPFC activity (F[1,54]=4.7, p=0.04; Fig. 6A).
Follow-up within-group conditional effects indicated that among HIV- CB users, more use
was linked with less error-related mPFC deactivation (β=0.7, t[24]=2.0, p=0.06). Whereas,
among CB using PLWH, mPFC activity was not correlated with lifetime use (β=-0.2,
t[28]=-0.7, p=0.5). We did not observe any significant associations of LIFETIME
AMOUNT on error-related PCC activity. Similar effects were observed when assessing
times using CB over the lifetime (Supplemental Figure S2). Interestingly, while CB users
did not display worse medication management performance relative to non-users
(F[1,99]=0.8, p=0.4), across all CB users, we observed a relationship between LIFETIME
AMOUNT and MMT scores (Fig. 6B) such that, more use was linked with poorer MMT
performance (F[1,50]=8.5, p=0.005). No relationship between CB use and self-reported
cognitive failures was observed (CFQ; p’s>0.8; Fig. 6C).
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Figure 6. Impact of CB use on brain and behavior. A) Among HIV- controls, reduced
error-related mPFC deactivations were linked with more lifetime CB use (although the
within-group conditional effect did not reach significance; p=0.06) whereas, among
PLWH, error-related mPFC activity was not associated with use. B) When controlling for
past month nicotine use, more lifetime CB use was associated with poorer MMT
performance (p=0.005) similarly for both HIV+ and HIV- groups (HIV x AMOUNT:
p>0.4) C) Lifetime CB use was not associated with self-reported cognitive failures (CFQ
total score; p’s>0.8).
1.5. Discussion
HIV is characterized by a progressive neurocognitive decline that can impact
everyday functions, including those critical for ongoing disease management. Emerging
evidence indicates that PLWH also exhibit a lack of insight into their cognitive deficits
which may manifest in the laboratory as diminished error recognition [81-84]. To delineate
altered error-related brain activity among PLWH, we employed a modified Go/NoGo task
where participants indicated awareness of their errors. We observed that error-related aI
activity was linked with fewer objectively measured commission errors across all
participants and fewer subjectively reported cognitive failures among HIV- participants.
Regarding error awareness, more insula activation and more PCC deactivation was linked
with aware (vs. unaware) errors, and such PCC deactivation correlated with fewer selfreported cognitive failures across all participants. Regarding group effects, PLWH lacked
error-related deactivation in two DMN regions (i.e., PCC, mPFC), deactivations which
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were observed among HIV- participants and were associated with fewer commission
errors. Importantly, we also documented clinically-relevant implications for such altered
PCC responsivity, such that reduced deactivations were linked with poorer medication
management abilities across all participants. Regarding CB-related effects, lifetime use
was associated with reduced error-related mPFC deactivation among CB using HIVparticipants as well as poorer medication management abilities across all CB users. Taken
together, these results demonstrate that insufficient DMN suppression, linked with HIV
infection and chronic CB use among HIV- participants, has real-world consequences for
medication management abilities.
EAT behavioral outcomes replication. Increasing confidence in our neuroimaging
outcomes, we largely replicated previously reported behavioral effects within the EAT.
First, error and error awareness rates observed across our sample were similar to those
previously documented among nondrug using [58], CB using [54], and cocaine using
participants [60]. Second, our participants demonstrated lower accuracy, yet higher
awareness of errors under the NoGo: Stroop (vs. repeat) condition which is consistent with
prior studies (e.g., [54, 59]) and the interpretation that the NoGo: Stroop rule was more
difficult to monitor [58]. Third, we replicated previously reported RT reductions on Go
trials following aware errors, yet RT slowing following unaware errors [54, 58, 59]. Such
RT differences bolster the argument that these two error types are qualitatively distinct and
differentially processed by the brain. Despite these task-related behavioral replications, we
did not observe anticipated group differences when considering number of errors, percent
of aware errors, or RT outcomes. Such null effects were initially surprising given that HIV
infection has been linked with reduced processing speed [149] and slower RTs in a Stroop
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task [150] and that CB use has been linked with reduced error awareness [54]. We speculate
that the lack of HIV-related effects observed herein, particularly regarding error rate and
RT, may be related to the dynamically adapting EAT difficulty manipulation.
EAT neuroimaging outcomes replication. Utilizing a contrast of NoGo correct
versus error [C-E] trials, we probed brain activity differentially modulated during cognitive
control success and failures. Consistent with meta-analytic outcomes compiling
neuroimaging results from cognitively demanding Go/NoGo tasks [100, 151], we observed
increased cognitive control-related brain activity on correct trials in the dmPC, bilateral
putamen, hippocampus, and occipital areas and, conversely, increased error-related
activity in the aI, dmPFC, as well as primary and supplementary motor cortex. Increased
aI and dmPFC activity has been consistently linked with error processing [152-155] and,
more generally, the monitoring of external cues indicating the need for increased cognitive
control deployment to achieve behavioral goals [132, 156]. As such, error-related aI and
dmPFC responsivity may facilitate behavioral adaptations to avoid future negative
outcomes [156]. Supporting this notion, we observed that increased error-related aI activity
was correlated with better cognitive control performance (i.e., fewer NoGo errors) across
all participants and less self-reported everyday cognitive failures among HIV- participants.
In contrast, among PLWH, a similar relationship between aI activity and self-reported
cognitive failures was not observed, which we suggest is reflective of a lack of insight into
cognitive alterations linked with HIV infection.
Utilizing a contrast of NoGo aware versus unaware [A-U] errors, we probed brain
activity related to explicit error awareness and observed increased activation in the bilateral
insulae, putamen, occipital lobe, and primary and supplementary motor areas. Our findings
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replicate prior work implicating the insula in error awareness [54]. Moving beyond error
awareness, the insula is theorized to play a critical role in interoceptive, emotional, and
other forms of subjective awareness [68] which may have particular significance for insight
into cognitive and affective alterations across neuropsychiatric conditions including
addiction [57]. Notably, we also observed greater bilateral PCC deactivations during aware
(vs. unaware) errors which correlated with fewer self-reported cognitive failures across all
participants and, unlike insula responsivity, has not been as widely emphasized in previous
EAT neuroimaging studies [54]. While, other work has linked reduced insular volume to
unawareness of memory loss among patients diagnosed with Alzheimer’s Disease [157]
and reduced insight among patients diagnosed with Schizophrenia [158], our findings
implicating PCC deactivations with both objective error awareness and subjective reports
of cognitive failures, indicate that the PCC may be critically important for insight into
cognitive alterations. Our PCC findings are also consistent with a key role for this region
in awareness [159, 160] and other work linking dynamic DMN activity with attention
[161], stimulus detection [107, 109], and intermittent cognitive failures [161-163],
HIV-associated reductions in error-related DMN suppression. Unlike HIVparticipants, PLWH displayed a lack of error-related deactivation in two DMN regions
(i.e., PCC, mPFC). Whereas HIV- participants displayed robust PCC and mPFC
deactivations following NoGo errors (and to a certain extent, on the trials immediately
preceding and succeeding those errors), such DMN regional activity among PLWH
remained relatively stable across trial types. Such deactivations play a causal role in taskvigilance [164] such that insufficient DMN suppression often precedes and is predictive of
intermittent attentional lapses [161-163, 165]. Primate electrophysiology work has also
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shown that PCC neurons become deactivated following errors and, importantly, that such
deactivation is necessary for new learning [166]. Taken together, such observations suggest
that insufficient error-related DMN suppression may contribute to poor task performance
and the disruption of behavioral adaptation [112, 166]. Such DMN suppression may reflect
the reallocation of limited cognitive resources from task-irrelevant mental operations
toward external task demands [112]. Errors in the EAT are particularly salient task events,
indicating that the participant must now execute an additional task behavior (i.e., press
button-2 on the next Go trial [Awareness-trial] instead of the usual button-1). As such,
error-related DMN suppression may be advantageous and reflect the re-deployment of
attentional resources toward the task in preparation for the subsequent Awareness-trial and
the avoidance of future errors. Indeed, greater error-related PCC deactivations were linked
with fewer errors among HIV- participants. We speculate that a lack of error-related DMN
suppression among PLWH is indicative of a reduced ability to disengage task irrelevant
mental operations and re-deploy attentional resources toward the task. Whereas altered
task-related DMN suppression has been linked with various neuropsychiatric conditions
[62, 111-119], one differentiating aspect of our study is linking this cognitive neuroscience
mechanism to HIV-associated neurobiological alterations and clinically-relevant
implications.
Real-world implications of HIV-associated brain alterations. Speaking to
clinically-relevant implications, across all participants, we observed that reduced errorrelated PCC deactivation correlated with poorer performance on a behavioral measure of
medication management abilities. Accumulating evidence links poorer HIV medication
management with worse neurocognitive outcomes, particularly executive dysfunction
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[128, 129, 167-169]. Although antiretroviral therapies significantly improve clinical
outcomes and prolong life for PLWH [86, 87], strict medication adherence is crucial for
success [87-90] and adherence rates remain unacceptably low (40-67%) [96]. Our results
indicate that diminished error-related PCC deactivation among PLWH may contribute, in
part, to these low adherence rates. We speculate that insufficient error-related DMN
suppression may reflect an individual’s reduced ability to disengage distracting thoughts
and to maintain attentional focus on a complex task. Providing some support for this
perspective, we observed that the magnitude of error-related PCC deactivation mediated
the effect of HIV serostatus on medication management abilities. We speculate that
interventions facilitating DMN suppression (e.g., mindfulness-based practices, workingmemory training, [170, 171]), may be beneficial for PLWH and the challenges they face.
Noteworthy, self-reported cognitive failures were not significantly associated with
medication management ability potentially suggesting a lack of self-awareness of one’s
cognitive abilities which has been previously highlighted in the HIV literature [172, 173].
Impact of chronic CB use on brain and behavior. We found that lifetime amount of
CB used was correlated with reduced error-related mPFC deactivation among HIVcontrols and reduced medication management abilities across all participants. Specifically,
more CB use by HIV- participants was linked with reduced mPFC deactivations such that,
at higher levels of use, HIV- participants’ brain responsivity approached that of PLWH.
Our results are consistent with other EAT studies that have documented reduced mPFC
deactivations following NoGo errors among drug users (i.e., ecstasy, cannabis), in the
absence of behavioral performance deficits [174]. In addition, other studies have linked
chronic CB use with increased mPFC activity across a variety of cognitive and emotional
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tasks [175]. While we did not observe group differences (CB+ vs. CB-) in medication
management abilities or brain activity, we did find that, among CB users, more lifetime
use was linked to poorer medication management abilities. Given the complex effects of
CB use duration [46], heaviness [40, 44], and age of regular use onset [45] on cognitive
alterations among PLWH, our results may suggest that CB’s impact on the brain and
behavior is dependent on use history. However, within the range present in our sample of
PLWH, amount of lifetime use was not associated with further reductions in error-related
mPFC deactivation, suggesting that the impact of CB use on medication management
abilities, may be related to another neurobiological mechanism.
Limitations. Our experimental design allowed us to consider the separate and
combined effects of HIV and CB on cognitive control and error-related brain activity. Yet,
our results should be considered in light of methodical limitations. First, given the design’s
cross-sectional nature, we cannot determine whether group differences in brain or behavior
are caused by HIV and/or drug use or whether they represent other preexisting social,
environmental, genetic, or personality risk factors that may predispose one to contracting
HIV or using CB. Large-scale, longitudinal research is needed to disentangle the
antecedents and consequences of both HIV and CB use. Second, while we collected a broad
range of demographic, health, and cognitive-behavioral data from participants, additional
variables that may have been of interest were not available. Specifically, socioeconomic
status (SES) is known to exert a profound impact on a wide range of health and quality of
life outcomes with many indirect downstream consequences. As such, the impact of SES
on HIV and CB effects on the brain should be considered in future work. Third, we were
unable to characterize the impact of CB use onset before versus after HIV seroconversion
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due to a lack of statistical power. Fourth, results have been mixed regarding the MMT-R’s
ability to map to self-reported medication adherence [130]. However, self-report
assessments of medication adherence may not be accurate particularly when considering
potential lack of insight [81, 176]. We suggest that the MMT-R is a validated, objective
behavioral measure of medication management ability that provides a useful proxy for an
individuals’ capacity to adhere to complex medication regimens. Nonetheless, future
research with improved operationalizations of actual medication adherence may want to
examine other factors beyond medication management ability (e.g., social, environmental,
financial) influencing adherence outcomes. Finally, although often implicit in mediation
models, we do not assume causality between variables included given the cross-sectional
and observational nature of our study design [146, 147]. Longitudinal designs and/or those
implementing experimental manipulations are better suited for establishing causal
relationships in mediation models [147, 177-179].
Conclusions. Our results demonstrate insufficient error-related DMN suppression
linked with HIV infection, as well as chronic CB use among HIV- participants, and
associated with clinically-relevant consequences for medication management behaviors.
Delineating this cognitive neuroscience mechanism may provide heuristic value for
strategies to improve medication adherence. As insufficient DMN suppression appears to
be a common endophenotype across various neuropsychiatric conditions, our results
further highlight the importance and ubiquity of this cognitive neuroscience perspective.
Given robust evidence that DMN suppression is linked with attention toward external
stimuli, we posit that certain HIV and CB-associated neurocognitive alterations may stem
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from a reduced ability to disengage task irreverent mental operations that ultimately hinder
cognitive control, error processing, and behavioral adaptation.
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CHAPTER 2
Altered Insula Functional Connectivity

2.1. Summary
Chronic inflammation in the central nervous system (CNS) is one mechanism
through which human immunodeficiency virus (HIV) may lead to progressive cognitive
decline. Given the anti-inflammatory properties of cannabis (CB), prevalent use among
people living with HIV (PLWH), and emerging evidence implicating the insula as a
neurobiological target of both, we examined how HIV and CB impact insular circuitry and
immune function. We assessed independent and interactive effects of HIV and CB on the
resting-state functional connectivity (rsFC) of three insula subregions among 106
participants across four groups (co-occurring: HIV+/CB+, n=32; HIV-only: HIV+/CB-,
n=28; CB-only: HIV-/CB+, n=24; controls: HIV-/CB-, n=22). Participants completed a
battery of well-validated instruments including assessments of somatic complaints and
motor dexterity. Blood samples quantified HIV disease severity (viral load), immune
function (T-cell counts), and inflammation (tumor necrosis factor alpha [TNF-a]). We
observed interactive HIVxCB effects on the rsFC strength between two anterior insula (aI)
subregions and sensorimotor cortices such that, CB use appeared to normalize altered rsFC
observed among non-using PLWH. Specifically, compared to controls, HIV-only and CBonly groups displayed decreased dorsal anterior insula (DI) - postcentral gyrus rsFC and
increased ventral anterior insula (VI) - supplementary motor area (SMA) rsFC, whereas
the co-occurring HIV+/CB+ group displayed DI and VI rsFC more akin to that of controls.
Altered DI - postcentral gyrus rsFC correlated with reduced somatic complaints across all
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participants and increased inflammation (TNF-α) among PLWH. These outcomes
implicate insula - sensorimotor neurocircuitries in the context of HIV and CB and are
consistent with prior work suggesting CB use may normalize insula functioning among
PLWH. Additionally, our results linking insula rsFC with TNF-α levels, begin to elucidate
potential inflammatory mechanisms through which CB use may impact brain function in
the context of HIV.

2.2. Introduction
Human immunodeficiency virus (HIV) attacks the immune system and causes
chronic inflammation which, when left unconstrained, can lead to opportunistic infections
and cognitive decline [3, 4]. HIV-associated cognitive decline can include impairments in
learning, executive function, processing speed, and motor abilities [8, 9] that are often
accompanied by mood disturbances and somatic complaints, further adversely impacting
daily life [79, 180]. As chronic inflammation in the central nervous system (CNS) is one
mechanism through which HIV may lead to progressive cognitive declines [181, 182],
leveraging the anti-inflammatory properties of cannabis (CB) [183, 184] has been of
interest [38, 185]. Both recreational and medicinal CB use is prevalent among people living
with HIV (PLWH) [26-29] and is linked with reduced inflammatory biomarkers in cerebral
spinal fluid (CSF) and blood [28, 34, 35]. PLWH frequently report using CB to relieve
somatic complaints including pain, nausea, loss of appetite, as well as anxious or depressed
mood [47, 186]. That said, the perceived versus actual physiological and psychological
effectiveness of CB use remains to be clarified [39-42]. As such, there is a need to more
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fully elucidate CB’s impact on objectively measured markers of inflammation, cognition,
and brain function in the context of HIV.
Blood inflammatory cytokines are an often-examined biomarker when considering
CB use among PLWH [28, 34, 35]. In particular, the proinflammatory cytokine, tumor
necrosis factor alpha (TNF-a), is believed to contribute to HIV pathogenesis [187]. TNFa is produced during acute inflammation and triggers a range of cellular responses and
production of several immune system molecules. For example, TNF-a modifies the
permeability of the blood-brain barrier allowing easier movement of peripheral immune
cells into the brain [188] and preclinical work has causally linked TNF-α with
neuroinflammatory-induced cognitive deficits [189]. TNF-a levels are elevated among
PLWH compared to age-matched controls [190] and are associated with disease
progression [191] such that they are predictive of time until HIV-associated dementia onset
[192]. On the other hand, a decline in TNF-a levels may be an efficacy marker of antiviral
therapy (ART) [193-195]. Preclinical research has also demonstrated that both cannabinoid
administration and cannabinoid receptor simulation inhibit the production and
inflammatory action of TNF-α and, in turn, mitigate neuronal damage [196-198]. Taken
together, such evidence suggests that TNF-α is likely a critical mediator of
neuroinflammatory-induced cognitive alterations and thus, may be a mechanism by which
HIV and CB modulate brain function.
Given that cognitive performance can be temporarily maintained by the brain’s
compensatory reallocation of functions to other available reserves [47, 199, 200],
examining the impact of HIV and CB on inflammatory markers and brain function may
offer enhanced insight into underlying mechanisms that forecast trajectories of
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neurocognitive decline [47]. While structural and functional alterations in the basal ganglia,
frontal cortex, and hippocampus [10-12, 14, 201] are commonly reported among PLWH,
emerging evidence also implicates the insula [202, 203]. The insula’s functional
connectivity with other brain regions has been linked to inflammatory responses and
associated somatic symptoms [55, 56]. Specifically, work among rheumatoid arthritis
patients (a disease also characterized by chronic inflammation) demonstrated reduced
insula and sensorimotor cortex activity following infusion of an anti-TNF-α monoclonal
antibody that was associated with later somatic symptom mitigation [204]. Further linking
this neurocircuitry with inflammation, altered resting-state functional connectivity (rsFC)
between the insula and various primary and supplementary motor and somatosensory
regions has been observed among arthritis patients [205].
Given HIV and CB-related effects on inflammatory markers, it is unsurprising that
both conditions are also associated with altered insula and somatosensory cortex activity.
For example, PLWH (vs. HIV- individuals) display increased insular and sensorimotor
cortex activation during hand movement tasks and reduced insula gray matter volume,
which correlates with immune system deterioration [53]. Additionally, one study not only
demonstrated distinct HIV and CB effects on left anterior insula (aI) activity during a
cognitive interference task, but also a HIVxCB interaction such that CB use appeared to
normalize reduced aI activity among PLWH [51]. Other evidence of a normalizing CB
effect among PLWH has been observed when considering graph theoretic metrics of local
and long-range rsFC across the whole brain [52]. However, interactive HIVxCB impacts
on insula-centric rsFC networks have yet to be fully considered. As the insula’s various
cortical and limbic connections are thought to play a role in cognitive [61, 62], motor [63,
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64], interoceptive, and pain processing [65-68], examining alterations in insular rsFC may
help elucidate specific neurobiological markers of HIV and CB-related inflammatory
effects with implications for cognitive functioning.
A variety of methodological approaches including cytoarchitectonic mapping
[206], tractography [207], meta-analysis of task-based brain activity [208-210], and rsFC
[211-214] have generally reached a consensus view that the insula can be parsed into at
least three subregions; the ventral aI (VI), the dorsal aI (DI), and the posterior insula (PI).
The PI, and its connections to premotor, sensorimotor, and supplementary motor cortices,
is thought to be involved in sensorimotor and pain processing [215-217], whereas VI
circuitry has been linked to subjective processing of affective states and the DI implicated
in cognitive control-related operations [212, 214]. That said, both anterior subregions’
engagement during a wide-range of mental operations likely indicates that they are more
generally involved with the integration of somatosensory, motor, affective, and cognitive
information allowing for context-appropriate behaviors [215-217]. As these subregions, to
a degree, display functional specialization [208-210], assessing rsFC patterns of precise
subregions may provide a more nuanced characterization of altered insula connectivity in
the context of HIV and CB.
Utilizing a cross-sectional, between-groups (co-occurring: HIV+/CB+; HIV-only:
HIV+/CB; CB-only: HIV-/CB+; controls: HIV-/CB-) experimental design, we assessed the
interactive effects of HIV serostatus and chronic CB use on rsFC of three insula subregions.
We then explored relationships between rsFC circuits demonstrating interactive HIVxCB
effects and measures of somatic complaints and motor function. We further examined
associations between rsFC circuits and measures of immune system function (CD4+ T-cell
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counts), inflammation (TNF-a plasma levels), and CB use amount. We addressed three
main empirical questions involving group-effects, implications for sensorimotor function,
and inflammation/immune function. Regarding group-effects, we expected altered insula
subregion rsFC among HIV-only and CB-only participants relative to controls and cooccurring participants (i.e., HIVxCB interaction). Regarding sensorimotor implications,
we expected rsFC circuits demonstrating interactive HIVxCB effects, to be linked with
measures

of

somatic

complaints,

and/or

motor

abilities.

Finally,

regarding

inflammation/immune function, we expected CD4+ T-cell counts and plasma TNF-a levels
to be elevated among the HIV-only (vs. co-occurring) participants and to be correlated with
altered insular rsFC.

2.3. Methods
Participants. A sample of 106 participants was stratified into four groups based on
HIV serostatus and CB use history (co-occurring: HIV+/CB+, n=32; HIV-only: HIV+/CB, n=28; CB-only: HIV-/CB+, n=24; controls: HIV-/CB-, n=22). Participants were recruited
from community-based organizations providing health care services throughout MiamiDade County. All participants were 18-60 years old to minimize the presence of other
chronic conditions (e.g., hypertension, diabetes), as well as the potential interactive effect
of HIV and aging on neurocognition [120-124]. Additional exclusionary criteria included:
current Hepatitis C infection, English non-fluency or illiteracy, less than an eighth-grade
education level, severe learning disability, serious neurological disorder, severe head
trauma with loss of consciousness >30 min, severe mental illness with psychotic or
paranoid symptoms, or MRI contraindications. All PLWH in this study were taking
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antiretroviral medications, were diagnosed with HIV 9.3±8.9 (mean±SD) years prior to
assessment, and had no history of opportunistic infections affecting the CNS. All CB using
participants reported a history of regular use (operationalized as at least once per week for
three straight months) and used at least 20 times in the past year. CB non-using participants
met the following criteria: no history of CB dependency, no CB use in the past month, and
a negative urine THC screen. Past use of and dependence on other substances, including
alcohol, nicotine, cocaine, amphetamines, benzodiazepines, or opioids was permitted
across each group to provide a more representative and generalizable sample. However,
participants were excluded they met criteria for current substance dependence (except CB
and nicotine) as assessed via the substance use module of the Diagnostic and Statistical
Manual of Mental Disorders (DSM)-5 Structured Clinical Interview [125].
Procedures. Study procedures were reviewed and approved by FIU’s Institutional
Review Board. Following informed consent, we collected blood, behavioral, self-report,
and MRI data across two study visits on different days. All participants were instructed to
refrain from any substance use (including CB use among CB+ participants) for 24-hours
before study visits to minimize acute pharmacological and/or withdrawal-related effects.
Upon arrival at both visits, participants completed substance use screening including urine
toxicology (Drug Check Cup, NXStep) and breathalyzer testing (AlcoMate Premium
Breathalyzer). During the first visit, blood specimens were collected and participants
completed a battery of behavioral tests and self-report questionnaires. Among PLWH,
blood samples were used to quantify HIV disease severity (HIV-1 viral load), immune
function (CD4+ T-cell count, lymphocyte subset counts, total white blood cell count), and
the proinflammatory cytokine, TNF-a, as well as other markers of pro-/anti-inflammatory
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responses (pro: interlukin(IL)-6; IL5; anti: IL-10). Among CB+ participants, samples were
used to quantify THC metabolite levels (plasma 9-carboxy-THC and THC to creatine
ratios) in urine. The second visit occurred within 1-month after the first, and during which
participants completed a 1-hour MRI scan after completion of additional self-reports.
Participants were compensated at the end of each visit.
Behavioral and self-report measures. Participants completed a battery of wellvalidated behavioral and self-report instruments. Herein, we focus on measures pertaining
to two domains in which insula engagement has been implicated namely, interoceptive
sensory processing [68, 218, 219], and fine motor ability [68, 214, 220, 221]. We utilized
t-scores on the DSM-oriented somatic complaints subscale of the Adult Self Report (ASR)
survey [222], that were corrected for age and biological sex based on national probability
samples, as a subjective measure of sensory processing. The Grooved Peg-Board Test
(GPT) was used as an objective measure of motor dexterity [223, 224]. The GPT is widely
used to characterize and diagnose HIV-associated neurocognitive disorder (HAND) [225].
We employed the standard administration procedure and testing apparatus (Lafayette
instruments #32025) consisting of a 5x5 matrix of keyhole-shaped grooves in varying
orientations with corresponding pegs. Individuals were instructed to place 25 pegs, one at
a time, into the grooves in a prescribed order as quickly as possible and then do the same
to remove them. Participants were timed for both the ‘place’ and ‘remove’ task portions.
Each participant completed the GPT task once with their dominate and once with their nondominate hand [226]. For each hand, total time (sec) to complete the task was recorded.
These times were then converted to t-scores corrected for age and biological sex based on
the Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery [227].
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MRI data acquisition and analysis. MRI data were collected on a GE Healthcare
Signa MR750, 3-Tesla scanner with 32-channel head coil. An 8-min resting-state scan with
eyes closed was collected with 42 slices (3.4mm thick) obtained in the axial plane using a
T2*-weighted, single-shot, gradient-echo, echo-planar imaging (EPI) sequence sensitive to
blood oxygenation level–dependent (BOLD) effects (245 volumes, repetition time
[TR]=2000ms, echo time [TE]=30ms, flip angle [FA]=75°, field of view=220mm, 64x64
matrix, voxel size = 3.44 x 3.44 x 3.40 mm3). T1-weighted structural images were obtained
using a magnetization-prepared rapid gradient-echo (MPRAGE) sequence (TR=2500ms;
TE=3.7ms; FA=12°; voxel size=1mm3).
Resting-state functional MRI (rs-fMRI) data were first denoised using dwidenoise
(MRtrix3) [228-232] which utilizes Marchenko-Pastur principal component analysis (MPPCA) to estimate and remove Gaussian thermal noise from MRI data, including fMRI data
[233], based on random matrix theory. Subsequent preprocessing was performed with
FMRIPREP v1.5.0 [133], a Nipype-based tool [134] often employing Nilearn [135]. T1weighted

structural

volumes

were

corrected

for

intensity

non-uniformity

(N4BiasFieldCorrection v2.1.0) [136] and skull-stripped (antsBrainExtraction.sh v2.1.0).
Nonlinear registration (ANTs v2.1.0) was performed to spatially normalize T1-weighted
volumes to the ICBM-152 asymmetrical template v2009c [137]. Functional data were
slice-time corrected to the middle of each TR using 3dTshift (AFNI v16.2.07) [139] and
motion corrected using MCFLIRT (FSL v5.0.9) [138]. Functional images were then coregistered to corresponding T1-weighted volumes using boundary-based registration
(2mm3 isotropic voxels) [143] with 9 degrees of freedom via bbregister (FreeSurfer v6.0.1).
The motion correction transformations, functional-to-anatomical transformation, and
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anatomical-to-template warp were all concatenated and applied in a single step using
Lanczos interpolation (antsApplyTransforms ANTs v2.1.0). Physiological noise regressors
were calculated applying CompCor [234]. Principal components were estimated for
anatomical (aCompCor) variants. A mask to exclude signal with cortical origin was
obtained by eroding the brain mask. Cerebral spinal fluid (CSF) and white matter (WM)
masks were subsequently calculated within this non-cortical mask in T1w space, after their
projection to the native space of the functional scan. Three aCompCor components were
calculated for both the CSF and WM masks. Frame-wise displacement [235] was also
calculated for each functional run using the Nipype implementation.
AfNI’s 3dTproject was used to perform simultaneous denoising of nuisance
regressors and bandpass filtering. Nuisance regressors included the six aCompCor
components (3 CSF, 3 WM) [236], the six motion parameters and their derivatives, and
TRs acquired during MRI stabilization (non-steady state) as determined by FMRIPREP. A
0.01 to 0.1 Hz bandpass filter was applied and functional volumes with framewise
displacement (FD) greater than 0.35mm, and the timepoints immediately preceding and
following, were censored. This resulted in 158 temporal degrees of freedom (DOF). Not
all participants could be further processed due to temporal DOF violations resulting in 93
participants for subsequent analyses (co-occurring: HIV+/CB+, n=28; HIV-only:
HIV+/CB-, n=27; CB-only: HIV-/CB+, n=21; controls: HIV-/CB-, n=17). An average of
6.2±6.0% of TRs were censored across all participants. Groups did not significantly differ
in the number of censored TRs (HIV: F[1, 93]=0.7, p=0.4; CB: F[1, 93]=1.0, p=0.3;
HIVxCB: F[1, 93]=0.1, p=0.8), or in mean FD (HIV: F[1, 92]=0.04, p=0.9; CB: F[1,
92]=0.81, p=0.4; HIVxCB: F[1, 92]=0.001, p=0.98). As motion is known to influence
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functional connectivity measures [237, 238], mean FD was also included as a covariate in
group-level rsFC assessments.
Separate first-level rsFC analyses were conducted for three seeds each in both the
left and right insula. The three seeds (i.e., DI, VI, and PI; Online Resource Fig 1) were
defined using Chang and colleagues (2013) parcellation based on coactivation during a
variety of tasks and rsFC patterns across the literature [214]. To reduce potential partial
volume effects, these seeds were then thresholded at 0.85 probability, as described in
Fedota et al., (2018) [239], and resampled to each participants’ rs-fMRI data space.
Timeseries from voxels within each seed were averaged and extracted for each participant.
For each hemisphere, the three seeds’ average timeseries were entered into a multiple
regression analysis (3dDeconvole & 3dREMLfit, AFNI). Including the three seeds in the
same deconvolution yielded connectivity maps representing each subregion's rsFC with
respect to (i.e., controlling for) the rsFC of the other two insula subregions. Lastly, a Fisher
z-transform was applied to the resulting partial correlation maps to ensure a normal
distribution.
Group-effect analyses were conducted within a sample-specific whole-brain mask
that included those voxels in which ≥50% of participants’ rs-fMRI scans had a non-zero
value, yielding a final mask with 272,561 voxels (2mm3 isotropic). Overall rsFC maps were
generated for each insula seed across the sample via whole-brain, one-sample t-tests (twotailed, 3dTtest++). The resulting rsFC maps were thresholded at pFWE-corrected <0.05, pvoxelwise=0.0001,

with minimum cluster extents (ranging from 9 to 11 voxels) determined for

each map using 3dClustSim with spatial autocorrelation correction [145]. Additionally,
pairwise dependent-samples t-tests (two-tailed, 3dTtest++) were conducted for each
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hemisphere to compare subregion rsFC (e.g., right DI versus right VI rsFC maps). The
resulting comparison maps were thresholded at pFWE-corrected <0.05, pvoxel-wise=0.001, with a
minimum cluster extent ranging from 37 to 40 voxels across the different subregion
comparisons. Finally, a whole-brain, two-way, HIVxCB ANOVA (3dMVM) was
performed for each seed comparing the main effects of HIV and CB, and identifying any
interaction effects. Age, sex, FD, and whether the participant was a current cigarette
smoker (NIC; operationalized as smoking at least 8 times in the last month) were entered
as covariates. Main effects of HIV and CB, as well as interaction effects, were thresholded
at pFWE-corrected <0.05, pvoxel-wise=0.001, with the minimum cluster extent ranging from 32 to
43 voxels across the different subregions.
Relationships between rsFC, behavior, and inflammation. For graphical
examination and follow-up analyses, we extracted the average z-values (normalized partial
correlation coefficients) from each seed’s whole brain rsFC map averaging across all nonzero voxels within clusters/regions of interest (ROIs) identified via HIVxCB group-effect
analyses. To assess brain-behavior relationships, we conducted partial Pearson’s
correlations (SPSS, v.26) between rsFC values and measures of somatic complaints, and
motor dexterity when including the following variables as covariates: HIV and CB group
membership, age, sex, FD, and NIC status. A Bonferroni correction (acorrected = 0.025) for
multiple comparisons was applied (number of ROIs tested, n=2). Next, we examined partial
correlations between DI and VI rsFC showing HIVxCB effects and measures of immune
function (CD4+ T-cell count) and inflammation (plasma TNF-a levels) among PLWH,
while controlling for CB group membership, age, sex, FD, and NIC status (Bonferroni
corrected for number of ROIs tested, n=2, acorrected = 0.025). We also examined whether DI
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and VI circuits showing HIVxCB effects were related to CB use (times using CB over the
lifespan) among CB-using participants while controlling for HIV group membership, age,
sex, FD, and NIC status. As the lifetime CB use variable was right-skewed, it was first
log10 transformed. Exploratory follow-up partial correlations examining relationships
between lifetime CB use and measures of inflammatory biomarkers within the co-occurring
group were also conducted.

2.4. Results
Group characteristics. Groups did not differ in terms of age or education when
considering main and interaction effects in HIVxCB ANOVAs (Table 1; p’s>0.2) nor in
race, ethnicity (Table 1; p’s>0.3), or history of major depressive episodes (Supplemental
Table S1; p’s>0.2) when considering Chi-square tests comparing HIV+ versus HIV- and
CB+ versus CB- groups. However, the HIV+ groups included a higher percentage of males
(80.0%) than the HIV- groups (55.3%; c2[1,93]=8.2, p=0.006), consistent with national
estimates regarding the sex distribution (81% male) of new HIV diagnoses [240]. This
difference was driven by the female/male composition among the CB+ groups (cooccurring vs. CB-only: c2[1, 93]=6.6, p=0.014), but not the CB- groups (HIV+/CB- vs.
HIV-/CB-: c2[1, 93]=3.3, p=0.1).
CB-using groups (co-occurring vs. CB-only) were matched on self-reported
measures of CB exposure (i.e., use duration, past month use, lifetime use, Table 1; p’s>0.1)
and plasma THC measures (Supplemental Table S2; p’s>0.1). As expected, the CB-using
groups had a higher percentage of participants meeting criteria for past (c2[1, 93]=17.9,
p<0.001) and current (c2[1,93]=9.6, p<0.002) CB dependence (Supplemental Table S3)
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and self-reported more past month (F[1, 93]=240.6, p<0.001) and lifetime use
(F[1,93]=48.1, p<0.001; Table 1).
Groups were largely matched on other drug use characteristics including past
dependence (e.g., alcohol, cocaine, Supplemental Table S3) as well as past month and
lifetime use (e.g., alcohol, cocaine, methamphetamine, prescription stimulants, heroin,
opiates, benzodiazepines, barbiturates, inhalants; Supplemental Table S4). The only
exceptions were nicotine and ecstasy, where the CB-using groups reported more past
month nicotine (F[1,93]=9.7, p=0.002) and more lifetime ecstasy use (F[1,93]=7.9,
p=0.006; Supplemental Table S4). Thus, whether a participant was a current cigarette
smoker was included as a dichotomous covariate (NIC) in all group-level analyses.
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Table 1. Demographic and drug use characteristics: Sample with resting-state data.
All
Participants
n=93

HIV+/CB+

HIV+/CB-

HIV-/CB+

HIV-/CB-

n=28

n=26

n=22

n=17

Group Effects (p’s)
HIVxCB

HIV

CB

Demographic
Age

34.8 (10.3)

33.3 (7.4)

37.5 (13.2)

32.8 (10.1)

35.8 (9.3)

0.7

0.9

0.2

Education (years)

13.8 (2.3)

13.8 (2.0)

13.6 (2.8)

13.8 (2.7)

14.4 (1.2)

0.4

0.4

0.7

Male, female

65, 28

26, 2

18, 8

14, 8

7, 10

-

0.006

0.04

AA, C, >1

48, 41, 4

14, 14, 0

14, 10, 2

11, 10, 1

9, 7, 1

-

0.5

0.3

Hispanic/Latinx

35

10

9

8

6

-

0.8

0.6

Age regular use

19.6 (6.7)

21.1 (6.5)

-

18.2 (7.1)

-

-

0.1☨

-

Years regular use

14.8 (11.5)

12.1 (8.9)

-

15.5 (12.1)

-

-

0.3☨

-

Past month(times)

12.8 (14.0)

23.4 (9.8)

0

0

0.7

0.7

<0.001

Lifetime (times)

2,141 (3,112)

3,556 (2,969)

282 (1,024)

24.4 (10.1)
4,182
(3,852)

7.8 (23)

0.4

0.7

<0.001

Cannabis use

Other drug use (past month, times)
Alcohol

2.2 (3.3)

2.2 (2.7)

2.2 (4.2)

2.9 (3.2)

1.4 (2.9)

0.3

0.9

0.3

Cocaine
Nicotine

0.02 (0.1)
4.3 (10.2)

0.1 (0.3)

0

0

0

0.2

0.2

0.2

7.2 (12.7)

1.5 (6.0)

7.2 (12.8)

0

0.7

0.7

0.002

Current cigarette
smoker (count)

16

8

3

5

0

-

0.9

0.08

NOTE. Data are expressed as either mean (standard deviation) or frequency in the total sample or specific groups. Drug use is selfreported number of times using each drug in the given timeframe (past month or lifetime). Group effects were assessed via either an
HIV x CB ANOVA, or for categorical variables, via Chi-square tests (one comparing HIV+ vs. HIV- groups and one comparing
CB+ vs. CB- groups). AA: African American, C: Caucasian, A: Asian, >1: more than one race. ☨independent samples t-test between
CB+ groups.
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Insula subregion rsFC: Replication. Consistent with previous reports [205, 213,
214], whole-brain rsFC maps for the three insula subregions (Figure 1A) indicated an
anterior-posterior gradient mirroring the topological subregion locations. Specifically, the
DI demonstrated robust rsFC with the dorsal medial prefrontal cortex (dmPFC),
cingulate/pre-supplementary motor area (SMA), bilateral dorsal striatum, supramarginal
gyrus, and bilateral precentral gyrus, extending into the inferior frontal gyrus. The VI was
functionally connected with the medial orbital gyrus and bilateral hippocampus. Whereas,
the PI displayed rsFC with the SMA/paracentral gyrus and postcentral gyrus. Pairwise
comparisons of insula subregion rsFC maps highlighted significant differences between
subregions’ rsFC (Figure 1B) with the DI being largely functionally connected with a
network of brain regions commonly involved in externally-focused cognitive control and
attention (i.e., medial and lateral prefrontal regions); the VI being differentially connected
with areas commonly displaying increased activity during rest and internally-focused
information processing (i.e., medial prefrontal cortex, posterior cingulate, hippocampus);
and the PI being differentially connected to sensorimotor cortices. We did not observe any
notable differences in rsFC maps between the left and right hemispheres. Replication of
expected insular subregion rsFC maps increased confidence in group-level outcomes.
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Figure 1. Differential insula subregion functional connectivity. (A) Resting-state
functional connectivity (rsFC) of the right (1) dorsal anterior (DI), (2) ventral anterior (VI),
and (3) posterior insula (PI) subregions (pFWE-corrected <0.05, pvoxel-wise=0.0001), was
observed notably in neighboring, but distinct, medial frontal and dorsal lateral cortices.
Significant anti-correlations are not displayed. The DI displayed rsFC, notably with the
dorsal medial prefrontal cortex (dmPFC), pre-supplementary motor area (pre-SMA),
bilateral dorsal striatum, bilateral precentral gyrus, inferior frontal gyrus, and
supramarginal gyrus. The VI displayed rsFC with the medial mid-orbital gyrus, posterior
cingulate, and bilateral hippocampus. The PI displayed rsFC with the SMA, paracentral
gyrus and postcentral gyrus. (B) Pairwise comparisons of insula subregions highlight
significant differences between (1) dorsal versus ventral, (2) ventral versus posterior, and
(3) posterior versus dorsal insula rsFC (pFWE-corrected <0.05, pvoxel-wise=0.001). Similar
outcomes were observed for left hemisphere seeds.
Insula subregion rsFC: Group effects. A significant HIVxCB interaction was
observed on rsFC strength between the left DI and a cluster (73 voxels) in the right
postcentral gyrus (Figure 2A, top). Specifically, the HIV-only and CB-only groups
displayed decreased rsFC relative to the control group, whereas the co-occurring group
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displayed rsFC more similar to that of controls (Figure 2B, top). An HIVxCB interaction
was also observed for rsFC between the right VI and multiple clusters in right dorsal
sensorimotor areas (Figure 2A, bottom), specifically in the SMA (102 voxels), primary
motor cortex (70 voxels), and precentral gyrus (39 voxels), as well as a cluster in the right
posterior/superior temporal gyrus (67 voxels). VI rsFC displayed an interaction pattern
converse to that from the DI, such that, HIV-only and CB-only groups demonstrated
increased rsFC with sensorimotor regions relative to the control and co-occurring groups
(Figure 2B, bottom). No significant group effects were observed when considering the
rsFC of other insula subregions.
Whole brain HIV and CB main effects for left DI and right VI rsFC largely
corresponded with the interaction effects described above. Specifically, a significant HIV
main effect was observed for right VI rsFC, such that all PLWH showed increased rsFC
with clusters in the right posterior/superior temporal gyrus, bilateral superior parietal lobe,
and bilateral middle frontal gyrus. Significant CB main effects were observed for left DI
rsFC such that CB-using (vs. non-using) participants displayed decreased rsFC with a
cluster (64 voxels) in the parietal-occipital sulcus. A significant CB main effect was also
observed on right VI rsFC such that all CB-using participants displayed increased rsFC
with a cluster in the right middle frontal gyrus and various bilateral clusters spanning the
lateral middle temporal gyrus and inferior parietal gyrus (see Supplemental Table S6 and
S7 for cluster coordinates).
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Figure 2. HIVxCB interaction effects for insula subregion functional connectivity. (A)
HIVxCB interaction on resting-state functional connectivity (rsFC) between the left dorsal
anterior insula (DI) and a cluster (73 voxels) in the (1) right postcentral gyrus and on rsFC
between the right ventral anterior insula (VI) and a cluster (102 voxels) in the (2) right
supplementary motor area (SMA) and smaller adjacent clusters in the paracentral gyrus (70
voxels) and primary motor area (39 voxels). (B) Normalized rsFC coefficients (z-scores)
were averaged across voxels in the (1) postcentral gyrus and (2) SMA and plotted for each
group. Visual inspection (to avoid circular analysis) indicated that both HIV-only (light
purple) and CB-only (dark green) groups displayed reduced DI - postcentral rsFC relative
to controls (light green). However, the co-occurring HIV+/CB+ group (dark purple)
displayed DI - postcentral rsFC more similar to that of controls. The opposite pattern was
observed for VI - SMA rsFC, such that HIV-only and CB-only groups displayed increased
rsFC relative to controls whereas the co-occurring group did not. (C) DI - postcentral gyrus
rsFC positively correlated with self-reported somatic complaints (p=0.014). (Green data
points: HIV- participants; purple: HIV+ participants). Unstandardized residuals are plotted
after regressing out effects of HIV and CB group membership, age, sex, FD, and NIC
status. (D) DI - postcentral gyrus rsFC negatively correlated with plasma levels of tumor
necrosis factor alpha (TNF-a; p=0.015). Significance was determined at a Bonferronicorrected alpha threshold (p<0.025). Error bars = standard error of the mean. Cluster
coordinates are reported in Supplementary Table S6 and S7.
Sensorimotor implications of rsFC alterations. Given the insula’s engagement
during interoceptive [68, 218, 219] and motor processing [68, 214, 220, 221], we
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considered HIV and CB effects on measures of functioning in these domains. We observed
a significant HIVxCB interaction on self-reported somatic complaints (F[1, 91]=4.8,
p=0.03; when controlling for age, sex, and NIC status) such that the co-occurring group
reported more somatic complaints compared to all other groups (Figure 3A; Table S5).
No significant group effects were detected for GPT scores (p’s>0.4; Figure 3B).
We then examined associations between insula subregion rsFC, somatic
complaints, and motor dexterity. As one participant’s rsFC z-scores from all ROIs were
deemed outliers (i.e., ±1.5 times the interquartile range), they were excluded from brainbehavior analyses. When controlling for HIV and CB group membership, age, sex, FD,
and NIC status, elevated DI - postcentral gyrus rsFC was associated with more selfreported somatic complaints (Figure 2C; r[84]=0.3, p=0.014), whereas VI - SMA rsFC
was not (p>0.5). We did not observe significant correlations between GPT scores and DI
or VI rsFC (p’s>0.08).

Figure 3. HIVxCB interactive effects on somatic complaints and motor abilities.
Group effects were assessed in HIVxCB ANCOVAs, controlling for age, sex, and NIC
status. Unstandardized residuals, after regressing out covariate effects, were averaged for
each participant group and plotted to examine the nature of any significant interactions.
(A) We observed a significant HIVxCB interaction on self-reported somatic complaints
(p=0.03) which was driven by more complaints among the co-occurring group compared
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to all others. (B) We did not observe any group-related effects when considering nondominate hand Grooved Peg Board Test (GPT) scores (p’s>0.4, nor dominate hand GPT
scores (p’s>0.7, data not shown). Error bars = standard error of the mean. Group means
and test statistics are reported in Supplementary Table S5.
rsFC relationships with immune function and inflammation. Of the PLWH in the
study (n=54), 74.1% had an undetectable viral load (i.e., <200 mRNA viral copies/mL).
Groups composed of PLWH (i.e., HIV-only vs. co-occurring) did not differ when
considering HIV-status measures (i.e., time since diagnosis, count with detectable viral
load, count with AIDS diagnosis, viral load [copies of HIV-1 RNA/mL]), immune function
(i.e., CD4+ T-cell count [cells/uL], CD8+ T-cell count, CD4+/CD8+ cell ratio, total Tlymphocytes, total white blood cell count), or markers of pro-/anti-inflammatory response
(pro: TNF-a, IL-5; IL-6; anti: IL-10; p’s>0.2, Table 2).
We then examined partial correlations between DI and VI rsFC showing HIVxCB
effects and measures of immune function (i.e., CD4+ T-cell count) and inflammation (i.e.,
TNF-a) among PLWH, while controlling for CB group membership, age, sex, FD, and
NIC status. Among PLWH, decreased DI - postcentral gyrus rsFC strength correlated with
increased TNF-a (r[45]=-0.4, p=0.015; Figure 2D). While reduced CD4+ T-cell counts
correlated with increased TNF-a levels (r[45]=-0.5, p<0.001), we did not detect a
correlation between CD4+ counts and insula rsFC (p’s>0.3). CD4+ count and TNF-a levels
did not correlate with VI rsFC nor measures of cognition (IQ), somatic complaints, or
motor ability (p’s>0.3). Follow-up exploratory analyses among the co-occurring group
(n=27) indicated that, when controlling for age and sex, neither CD4+ counts nor TNF-a
levels correlated with lifetime CB use amount (p’s>0.9).
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Table 2. HIV status and immune system markers: Sample with resting-state data.
All HIV+ Participants
n=54

HIV+/CB+
n=28

HIV+/CBn=26

Group
Effects
(p’s)

9.3 (8.9)

7.8 (6.9)

10.8 (10.6)

0.2

14

9

5

0.6

6

4
18,254.8
(69,658.7)

2
10,854.9
(40,853.7)

0.7

659.2 (305.9)

672.1 (282.3)

645.4 (334.6)

0.8

CD8 T-cell count (cells/uL)

1,064.9 (562.4)

993.2 (445.9)

1,142.2 (666.2)

0.3

CD4+/CD8+ cell ratio

0.755 (0.1)

0.774 (0.1)

0.736 (0.1)

0.8

Total T-lymphocytes (cells/uL)
Total white blood cells (thousand
cells/uL)

1,786.1 (676.9)

1,728.9 (546.5)

0.5

6,533.3 (2,002.0)

6,167.9 (1962.1)

1,847.7 (800.7)
6,926.9
(2,007.1)

HIV-status Measures
Time since HIV diagnosis (years)
Count with detectable viral load
(>200 copies/mL)
Count with AIDS diagnosis
Viral load (copies of HIV-1
RNA/mL)

14691.9 (57211.4)

0.6

Immune Function
CD4+ T-cell count (cells/uL)
+

0.2

Pro-/Anti-Inflammatory Response Makers
TNF-a

12.6 (6.3)

12.9 (7.2)

12.3 (5.2)

0.8

Interleukin-5

4.1 (20.6)

5.8 (27.9)

2.2 (7.1)

0.5

Interleukin-6

0.9 (2.7)

0.6 (1.3)

1.3 (3.7)

0.4

Interleukin-10

3.1 (3.2)

3.3 (3.7)

2.8 (2.6)

0.6

NOTE. Data are expressed as either mean (standard deviation) or as number of participants.
HIV-1 viral load assessed via the Abbott RealTime HIV-1 assay. Group effects were
assessed with independent samples t-tests or Chi-square tests comparing the co-occurring
and HIV-only groups.
2.5. Discussion
After replicating distinct rsFC patterns across insular subregions, we observed an
interactive effect of HIV infection and chronic CB use on rsFC between anterior insula
subregions (i.e., DI, VI) and multiple primary and supplementary sensorimotor areas.
Interestingly, DI and VI rsFC strength showed converse interaction patterns further
highlighting a functional distinction across subregions [219]. HIV-only and CB-only
groups (vs. controls) displayed reduced DI - postcentral gyrus rsFC that was linked with
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fewer somatic complaints across all participants, and increased inflammation (TNF-α)
among PLWH. VI - SMA rsFC showed the opposite pattern, such that HIV-only and CBonly groups (vs. controls) displayed increased VI - SMA rsFC. Similar to previously
reported interaction effects on brain function [51, 52], the co-occurring HIV+/CB+ group
displayed DI and VI rsFC more akin to that of controls, suggesting that CB use may, to a
degree, normalize altered insula functioning among PLWH. The currently observed
interactive effects of HIV and CB on insula – sensorimotor neurocircuitries which were
also linked with somatic complaints, and inflammatory markers, extends prior work and
sheds light on potential mechanisms through which CB use may impact brain function in
the context of HIV.
CB-related normalization of HIV-associated rsFC alterations. HIV-only and CBonly groups displayed decreased DI and increased VI rsFC with sensorimotor regions
relative to controls, yet CB use among PLWH in the co-occurring group appeared to
normalize rsFC strength to near controls’ levels. The currently observed interaction effects
on insula-specific rsFC are consistent with recent work by Hall and colleagues (2021)
showing that both HIV-only and CB-only groups presented with alterations in local and
long-range rsFC assessed via whole brain graph theoretic metrics, whereas a co-occurring
HIV+/ CB+ group did not [52]. Those authors posited that CB use may normalize
alterations in large-scale brain network organization observed among PLWH while
emphasizing that the cognitive implications of their observation remained unknown [52].
Our observation of a similar CB-related normalization of insula-centric rsFC among
PLWH extends prior work by identifying specific insula - sensorimotor neurocircuitries
and delineating rsFC relationships with measures of somatic complaints and inflammation.

66

Delineating specific alterations in insula - sensorimotor cortex circuitry. Our results
suggest that interactive HIV and CB effects on insular rsFC may be specific to the anterior
subregions. Further, our observation of decreased DI, yet increased VI rsFC associated
with HIV infection and CB use functionally dissociates these two aI circuits. Comparison
of VI and DI rsFC maps may aid interpretation of this dissociation, as we replicated DI
functional coupling with a network of brain regions commonly activated during cognitive
control and external task attention (e.g., dlPFC, superior parietal cortex) and VI coupling
with regions commonly activated during mind-wandering and subjective valuation (e.g.,
mPFC, posterior cingulate, hippocampus) [213, 215]. Given our observed dissociation of
HIV and CB-associated DI and VI rsFC alterations, and prior work delineating the
functional significance of these subregions’ distinct connectivity patterns [214, 218, 219],
we speculate that decreased DI and increased VI rsFC with sensorimotor cortical regions
could reflect prioritization of internal, over external, information integration during sensory
and motor processing.
Prior work has also identified the importance of aI - sensorimotor circuitry in the
context of concurrent HIV infection and CB use. For example, Meade and colleagues
(2018) identified an aI cluster showing an HIVxCB interactive effect on brain activity
during cognitive interference task blocks compared to control task blocks [51]. Our DI seed
closely corresponds to their aI cluster and we observed a similar HIVxCB interaction on
DI - postcentral gyrus rsFC, such that HIV-only and CB-only groups displayed decreased
aI activity but the co-ocurring HIV+/CB+ group did not [51]. Interestingly, Meade and
colleagues (2018) also observed activity in the postcentral gyrus, precentral gyrus, and
SMA during cognitive interference across all participants. In light of the results by Meade
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and colleagues (2018), and our current rsFC findings, we suggest that HIV and CB use
influences functioning in insula-sensorimotor neurocircuitries which is both discernable at
rest and linked with cognitive task performance.
Other findings delineating the impact of HIV and chronic inflammation on insulasensorimotor circuitry further supports our interpretation. For example, PLWH (vs. healthy
controls) have been shown to present with increased insula activation during a hand
movement task and reduced gray matter volume in the insula, premotor gyrus, and
supramarginal gyrus which was also associated with immune system deterioration.
Notably, this hand movement task engaged what those authors termed a “classical” motor
network, including the primary motor cortex, primary somatosensory cortex, cingulate
motor area, and cerebellum [53]. Additionally, similar to our results among PLWH, altered
rsFC between the insula and dorsal primary motor cortex has been observed among arthritis
patients [205]. Overall, our rsFC work supports and extends this prior knowledge,
suggesting that HIVxCB interactive effects, previously observed on task-based insula
responsivity [51, 53], may represent a more general alteration of the functional coupling
between the insula and sensorimotor cortex that is also observed during task-independent
states.
Implications for somatic complaints. Increased DI - postcentral gyrus rsFC was
associated with elevated somatic complaints across all participants when controlling for
both CB and HIV group membership and other relevant covariates. This observation
corresponds with recent work linking increased DI - postcentral gyrus rsFC with reduced
subjective well-being among elderly adults [241]. Given the insula’s widely reported
involvement in pain and introspective processing [65-67], one interpretation of this finding,
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while speculative, may be that reduced DI - postcentral gyrus rsFC observed among HIVonly and CB-only groups may be associated with reduced interoceptive awareness and, in
turn, lower self-reported somatic complaints. Overall, our results highlight the relevance
of DI rsFC when considering the underlying neurobiology of somatic complaints among
PLWH. As expected, we found that PLWH reported more somatic complaints than HIVparticipants and, despite reports of somatic symptom mitigation linked with CB use among
PLWH [47, 186], we observed that CB using PLWH actually reported more somatic issues
than non-using PLWH, consistent with prior observations [242]. These outcomes may, in
part, be explained by CB use being more likely among PLWH that report higher somatic
complaints given perceived symptom-reliving effects [47, 186].
Implications for motor functioning. While a similar insula - sensorimotor circuit
has been implicated in executing tasks involving both cognitive control [51] and motor
abilities [53], we did not observe significant relationships between insula rsFC circuits
displaying HIVxCB interactive effects and a behavioral measure of motor ability (i.e., GPT
scores). This suggests that while this network of regions is commonly engaged during
motor performance tasks, task-independent rsFC strength at rest is not necessarily related
to task-based motor ability. Additionally, motor ability did not significantly differ as a
function of HIV CB group membership. One interpretation of this finding is that PLWH
and chronic CB users are able to maintain normal motor ability, despite alterations in
supporting brain mechanisms, potentially through compensatory mechanisms [47].
Anti-inflammatory mechanisms of CB. While more research is needed to fully
understand the impact of CB use on inflammation and brain function among PLWH, our
results indicate that increased DI rsFC is linked with CB use and reduced inflammation
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(lower TNF-α levels). While there is little prior evidence linking TNF-α levels to brain
function among PLWH, emerging evidence suggests that elevated TNF-α may be a critical
contributor to symptoms associated with altered insula function [79]. For example, an
examination of patients with rheumatoid arthritis demonstrated that blocking circulating
TNF-α reduced insula and sensorimotor cortex activity which was associated with later
symptom mitigation [204]. That study was able to draw more causal conclusions about the
impact of TNF-α on insula - sensorimotor neurocircuitry than our correlational findings.
Nonetheless, our results begin to elucidate potential anti-inflammatory mechanisms
through which CB use may normalize brain function among PLWH and suggest that future
work could consider whether CB use reduces TNF-α levels among PLWH, modulates
insula - somatosensory cortex functional coupling, and/or is linked with improved
cognition.
Limitations. Our results should be considered in light of methodical limitations.
First, given the design’s cross-sectional nature, we cannot determine whether group
differences in brain function, inflammation, or behavior are caused by HIV and/or CB use
or whether they represent other preexisting social, environmental, genetic, or personality
factors that may predispose an individual to contracting HIV or using CB. Large-scale,
longitudinal research is needed to disentangle the antecedents and consequences of both
HIV and CB use. Additionally, our ability to detect individual differences in CB use
history, among CB using participant groups or inflammatory biomarkers, among HIV+
participant groups was limited given small within-group sample sizes. Second, we did not
collect recency of last CB use before plasma was sampled, cerebral spinal fluid (CSF)
levels of TNF-a, or inflammatory biomarker data from HIV- participants. Additionally, as
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the majority of PLWH in our sample had an undetectable viral load, our range of
inflammation and immune function biomarker levels was likely limited albeit, potentially
more representative of PLWH in the post-ART era. Finally, while our work controlled for
age effects, we did not have a large enough sample to assess complex interactive effects of
age with CB use duration in the context of HIV; however, these interactive trajectories may
be of interest in future research.
Conclusion. Our findings support and extend prior work, demonstrating HIV and
CB-associated alterations in insula - sensorimotor cortex neurocircuitries that were linked
with heightened inflammation, and normalized by CB use among PLWH. These results
begin to reveal potential anti-inflammatory mechanisms through which CB use may
impact brain function among PLWH.
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CHAPTER 3
Dysregulated Network Interactions

3.1. Summary
Altered activity within and between large-scale brain networks has been implicated
across various neuropsychiatric disorders. Three networks in particular have been
highlighted, the default mode network (DMN), the central executive network (CEN), and
the salience network (SN). However, patterns of network dysregulation that are associated
with human immunodeficiency virus (HIV), and further impacted by cannabis (CB) use,
have not yet been fully delineated. We examined the impact of HIV and CB on restingstate functional connectivity (rsFC) interactions of these large-scale networks and
associations with error awareness and error-related network responsivity. Participants
(N=106), stratified into four groups (HIV+/CB+, n=32; HIV+/CB-, n=28; HIV-/CB+,
n=24; HIV-/CB-, n=22), underwent fMRI scanning while completing a resting-state scan
and a modified Go/NoGo paradigm called the Error Awareness Task (EAT) that assesses
explicit error awareness and brain responsivity to errors. Blood samples quantified HIV
disease severity (viral load), immune function (white blood cell [WBC], T-cell counts),
and inflammation (tumor necrosis factor alpha [TNF-a]). We calculated resource
allocation indexes (RAIs), a measure quantifying the strength of rsFC between the SN,
DMN, and CEN, which has previously been used to delineate drug-related impacts on
large-scale brain networks. We then assessed separate and interactive effects of HIV and
CB on RAIs and explored relationships between measures of intrinsic network interactions,
immune function, and error awareness. We observed bilaterally reduced RAIs among
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PLWH that were driven by increased SN-DMN rsFC compared to HIV- participants. In
contrast, SN-CEN rsFC did not display differences across groups. Both decreased RAI and
increased SN-DMN rsFC were linked with reduced total WBC counts among virally
undetectable PLWH. Additionally, increased SN-DMN rsFC was linked to diminished
error awareness across all participants. While error-related DMN suppression was reduced
among PLWH, compared to HIV- participants, it was not significantly correlated with SNDMN synchrony during resting-state. These outcomes demonstrate altered large-scale
brain network interactions and altered task-based network responsivity among PLWH that
correspond with patterns of network dysregulation that have been linked to other
psychiatric conditions and may reflect an inability to disengage task irrelevant mental
operations, ultimately hindering error monitoring and behavior modification.

3.2. Introduction
The human immunodeficiency virus (HIV) is a chronic infection that enters the
central nervous system (CNS) and dysregulates the immune system [243].
Neuroinflammation due to HIV, combined with the interactive and additive impacts of
opportunistic infections, aging, and substance use, contributes to neurocognitive
impairments that have shown to persist in the antiretroviral therapy (ART) era [6, 244,
245]. In particular, the long-term impact of cannabis (CB) use in the context of HIV
infection, may be particularly relevant when considering interactive effects on
neurocognitive function given the prevalence of use among people living with HIV
(PLWH) [26-29] and frequent reports of CB use to relieve HIV-related symptoms [47,
186]. As neurocognitive impairments among PLWH negatively impact disease
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management, employment, and quality of life [246, 247], there is a need to identify
neurobiological alterations contributing to such symptoms [243, 248]. One systems-level
model of psychopathology [78, 249] suggests that the neurobiological underpinnings of
many neurodegenerative and neuropsychiatric conditions may be understood through a
common conceptualization of interactions between large-scale functional brain networks
[78, 249]. This framework has been employed to describe dysregulated brain function
associated with Alzheimer’s disease (AD), frontotemporal dementia (FTD), schizophrenia
[115], addiction [62, 116, 117], attention deficit hyperactivity disorder (ADHD) [118, 119],
and mood disorders [114]. The three widely recognized functional brain networks
implicated in this model are the default mode network (DMN), the central executive
network (CEN), and the salience network (SN; e.g. [62, 72, 78]). The DMN is primarily
engaged during intrinsic thought processes that arise independent of external stimuli and
is thought to be involved in internal and self-referential information processing [72-74],
whereas the CEN is engaged during tasks that demand attention and cognitive control and
is thought to be involved in processing external stimuli [75, 76]. Accordingly, DMN and
CEN function are negatively correlated and the SN is thought to be involved in toggling
neurocognitive resources between them in an effort to focus attention toward prioritized
information [71, 77, 78].
The resource allocation index (RAI) is a formerly developed measure that reflects
the interacting dynamics of these networks based on the hypothesized role of the SN in
allocating resources to the CEN and DMN [250]. The RAI has been used to evaluate
dysfunction in the relative balance between SN-DMN and SN-CEN connectivity within
this triple network model of psychopathology, including that among various substance use
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disorder populations [250-253]. For example, research has shown that the attentional and
cognitive deficits characterizing nicotine withdrawal are associated with reduced activation
in brain regions comprising the CEN, and implicated in cognitive control (e.g., the
dorsolateral prefrontal cortex [DLPFC]), and less suppression of activation in regions
comprising the DMN, and implicated in task-independent states (e.g., the posterior
cingulate cortex [PCC]) [250, 254-257]. These observations have led to the hypothesis that
the SN allocates attentional resources toward processing the symptoms of nicotine
withdrawal (e.g., craving), thereby biasing activity toward the DMN and away from the
CEN [62]. Indeed, reduced RAIs have been associated with a nicotine withdrawal state,
among dependent smokers, and diminished performance on a cognitive control task [250].
In line with the triple network model, accumulating neuroimaging evidence has not
only associated neurocognitive disorders with altered resting-state network connectivity
[62, 111-119, 258-269], but also with altered task-based network modulation [114, 117,
270, 271]. While evidence demonstrates small, albeit consistent, changes in network
interactions that distinguish task from rest states, task-evoked brain activity is related to
resting-state network organization [272]. These observations support the notion of an
intrinsic, standard architecture of functional brain organization that is highly similar across
both rest and a variety of tasks [272]. Thus, to fully understand how intrinsic network
organization contributes to cognitive impairments characterizing HIV and other
neuropsychiatric disorders, it may be beneficial to examine both resting-state network
interaction tendencies, and network responsivity during task events. In particular, lack of
appropriate DMN suppression during tasks is a common endophenotype seen across
various disorders [62, 111-119]; however, impairments in DMN suppression have rarely
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been examined among PLWH. As DMN suppression is thought to support task attention
[164] and detection of salient stimuli [109], insufficient suppression likely contributes to
task errors and a lack of error recognition. Proper recognition of errors is vital for everyday
functioning as it facilitates behavioral adaptation aiming to rectify past errors and avoid
future ones. Accumulating evidence suggests that PLWH may display metacognitive
difficulties such that they under report their cognitive failures when compared to objective
behavioral measures [81-84]. As these difficulties are potentially indicative of poor error
awareness that could serve to worsen the consequences of cognitive impairments on
disease management and everyday functioning, it is critical to understand how
dysregulated intrinsic and task-based network functioning relate to error awareness among
PLWH.
First, we aimed to examine independent and combined effects of HIV and CB on
intrinsic network coupling utilizing the RAI as a measure of relative SN-DMN and SNCEN interactions. Second, we examined associations between resting-state functional
connectivity (rsFC) and measures of inflammation (tumor necrosis factor alpha [TNF-a]
levels), immune system function (white blood cell (WBC) count, CD4+ T-cell count), and
viral load, among PLWH. Finally, to understand implications of aberrant intrinsic network
dynamics on error awareness and error-related brain responsivity, we examined relations
between network rsFC, and a behavioral measure of error awareness, as well as errorrelated network activity. We addressed three main empirical questions involving groupeffects, immune function/inflammation, and error processing. Regarding group-effects, we
expected reduced RAI among PLWH and CB users when compared to controls. Regarding
immune function/inflammation, we expected reduced RAI and altered network rsFC to be
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associated with decreased WBC and CD4+ T-cell counts and increased inflammation
among PLWH. Finally, regarding error processing, we expected reduced RAI and altered
rsFC to be linked with decreased error awareness and altered error-related network
responsivity.

3.3. Methods
Participants. A sample of 106 participants was stratified into four groups based on
HIV serostatus and CB use history (co-occurring: HIV+/CB+, n=32; HIV-only: HIV+/CB, n=28; CB-only: HIV-/CB+, n=24; controls: HIV-/CB-, n=22). Participants were recruited
from community-based organizations providing health care services throughout MiamiDade County. All participants were 18-60 years old to minimize the presence of other
chronic conditions (e.g., hypertension, diabetes), as well as the potential interactive effect
of HIV and aging on neurocognition [120-124]. Additional exclusionary criteria included:
current Hepatitis C infection, English non-fluency or illiteracy, less than an eighth-grade
education level, severe learning disability, serious neurological disorder, severe head
trauma with loss of consciousness >30 min, severe mental illness with psychotic or
paranoid symptoms, or MRI contraindications. All PLWH in this study were taking
antiretroviral medications, were diagnosed with HIV 9.3±8.9 (mean±SD) years prior to
assessment, and had no history of opportunistic infections affecting the CNS. All CB using
participants reported a history of regular use (operationalized as at least once per week for
three straight months) and used at least 20 times in the past year. CB non-using participants
met the following criteria: no history of CB dependency, no CB use in the past month, and
a negative urine THC screen. Past use of and dependence on other substances, including
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alcohol, nicotine, cocaine, amphetamines, benzodiazepines, or opioids was permitted
across each group to provide a more representative and generalizable sample. However,
participants were excluded if meeting criteria for current substance dependence (except CB
and nicotine) as assessed via the substance use module of the Diagnostic and Statistical
Manual of Mental Disorders (DSM)-5 Structured Clinical Interview [125].
Procedures. Study procedures were reviewed and approved by FIU’s Institutional
Review Board. Following informed consent, we collected blood, behavioral, self-report,
and MRI data across two study visits on different days. All participants were instructed to
refrain from any substance use (including CB use among CB+ participants) for 24 hours
before study visits to minimize acute pharmacological and/or withdrawal-related effects.
Upon arrival at both visits, participants completed substance use screening including urine
toxicology (Drug Check Cup, NXStep) and breathalyzer testing (AlcoMate Premium
Breathalyzer). During the first visit, blood specimens were collected and participants
completed a battery of behavioral tests and self-report questionnaires. Among PLWH,
blood samples were used to quantify HIV disease severity (HIV-1 viral load), immune
function (WBC count, CD4+ T-cell count), and inflammatory marker (TNF-a). The second
visit occurred within 1 month after the first and participants completed a 1-hour MRI scan
session and additional self-reports. Participants were compensated at the end of each visit.
MRI data acquisition and analysis. MRI data were collected on a GE Healthcare
Signa MR750, 3-Tesla scanner with 32-channel head coil. An 8-min resting-state scan with
eyes closed was collected with 42 slices (3.4mm thick) obtained in the axial plane using a
T2*-weighted, single-shot, gradient-echo, echo-planar imaging (EPI) sequence sensitive to
blood oxygenation level-dependent (BOLD) effects (245 volumes, repetition time
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[TR]=2000ms, echo time [TE]=30ms, flip angle [FA]=75°, field of view=220mm, 64x64
matrix, voxel size = 3.44 x 3.44 x 3.40 mm3). These same EPI parameters were also used
to collect six functional runs (169 volumes/run) while participants completed a Go/NoGo
motor inhibition paradigm called the Error Awareness Task (EAT) [54, 58-60]. Participants
performed this task during the 4 runs preceding, and 2 runs following, the resting-state scan
which is of primary interest. Herein we focus on the EAT’s behavioral measure of error
awareness and examine network responsivity to task errors. T1-weighted structural images
were obtained using a magnetization-prepared rapid gradient-echo (MPRAGE) sequence
(TR=2500ms; TE=3.7ms; FA=12°; voxel size=1mm3).
First, Gaussian thermal noise was estimated and removed from resting-state MRI
data utilizing dwidenoise (MRtrix3) [228-233]. Additional preprocessing was performed
with FMRIPREP v1.5.0 [133], a Nipype-based tool [134] often employing Nilearn [135].
T1-weighted

structural

volumes

were

corrected

for

intensity

non-uniformity

(N4BiasFieldCorrection v2.1.0) [136] and skull-stripped (antsBrainExtraction.sh v2.1.0).
Nonlinear registration (ANTs v2.1.0) was performed to spatially normalize T1-weighted
volumes to the ICBM-152 asymmetrical template v2009c [137]. Functional data was slicetime corrected to the middle of each TR using 3dTshift (AFNI v16.2.07) [139] and motion
corrected using MCFLIRT (FSL v5.0.9) [138]. Boundary-based registration (bbregister,
FreeSurfer v6.0.1) was used to co-register functional images to corresponding T1-weighted
volumes (2mm3 isotropic voxels) [143] with 9 degrees of freedom (DOF). Lanczos
interpolation (antsApplyTransforms ANTs v2.1.0) concatenated all motion correction
transformations (functional-to-anatomical, anatomical-to-template) and applied them in a
single step. Physiological noise regressors were calculated applying aCompCor [234].
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Specifically, cerebral spinal fluid (CSF) and white matter (WM) masks were calculated in
T1w space, within a mask excluding signal with cortical origin. Three aCompCor principal
components were then calculated for both the CSF and WM masks. Frame-wise
displacement [235] was also calculated for each functional run using the Nipype
implementation.
3dTproject (AFNI) was used to perform simultaneous nuisance regression and
bandpass filtering. Nuisance regressors included the six aCompCor components (3 CSF, 3
WM) [236], the six motion parameters, their derivatives, and TRs acquired during MRI
stabilization (non-steady state) as determined by FMRIPREP. A 0.01 to 0.1 Hz bandpass
filter was applied and TRs with framewise displacement (FD) greater than 0.35mm were
censored along with timepoints immediately preceding and following. This resulted in 158
temporal DOF. Not all participants could be further processed due to temporal DOF
violations in the denoising procedure resulting in 93 remaining participants (co-occurring:
HIV+/CB+, n=28; HIV-only: HIV+/CB-, n=27; CB-only: HIV-/CB+, n=21; controls:
HIV-/CB-, n=17). An average of 6.2±6.0% of TRs were excluded from each participants’
resting-state scan. Groups did not significantly differ in the number of censored TRs (HIV:
F[1, 93]=0.7, p=0.4; CB: F[1, 93]=1.0, p=0.3; HIV x CB: F[1, 93]=0.1, p=0.8), or in mean
FD (HIV: F[1, 92]=0.04, p=0.9; CB: F[1, 92]=0.81, p=0.4; HIV x CB: F[1, 92]=0.001,
p=0.98). As motion is known to influence functional connectivity measures [237, 238],
mean FD was included as a covariate in group-level rsFC assessments.
Timeseries were then standardized (shifted to a zero mean and scaled to a unit
variance) and averaged across voxels within four separate network masks (Nilearn,
NiftiLabelsMasker.fit_transform). These network masks were defined with the Functional
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Imaging in Neuropsychiatric Disorders (FIND) atlas which includes masks for an anterior
salience network (SN), a dorsal default mode network (DMN), a left executive control
network (labeled here as the central executive network; L. CEN), and a right executive
control network (R. CEN) [273, 274]. Networks in this functional atlas were identified by
applying an independent component analysis (ICA; MELODIC, FSL) to resting-state data
and visually identifying 14 canonical intrinsic functional connectivity networks out of the
of 30 generated components, based on previous work. The creation of this atlas is described
in more detail in Shirer et al., 2012 [273]. While we did not have specific hypotheses
regarding laterality of the CEN, we calculated separate RAIs for the left and right CENs to
replicate prior work [250, 252, 275]. Additionally, the RAI has formerly been calculated
with an ICA-based approach in which participant-specific timeseries are estimated by
regressing components of interest (resulting from a group-average ICA) back on to each
participant’s functional data [72, 250]. As such, we also report results from exploratory,
follow-up analyses using an ICA-based approach, in addition to the results from the atlasbased approach reported herein. Results from the ICA-based approach are described in the
supplemental material (Figure S1-2).
Correlation coefficients between the four network masks’ average timeseries were
computed for each participant (Nilearn, ConnectivityMeasure.fit_transform) and used as a
measure of rsFC strength between networks. We then computed the RAI to assess network
interactions [250] based on the hypothesized role of the SN toggling resources between the
CEN and DMN. Specifically, the RAI integrates a positive SN-CEN correlation and a
negative SN-DMN correlation such that higher RAI values indicate either positive
synchronization of SN with CEN and/or negative synchronization of SN with DMN [250].
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As done previously [250], we calculated the RAI by first performing fisher’s transforms to
standardized correlation coefficients ("") between the SN and the R. CEN ("" #$%&.()$ ),
L. CEN ("" #$%,.()$ ), and DMN ("" #$%./$ ) using formula 1. We then computed the
RAI for the left and right CEN using formula 2 and formula 3 respectively.

Formula 1.
1 ("" ) = 0.5 ∗ ln 8

(1 + "")
<
(1 − "")

Formula 2.
=. >?@ = 1("" #$%,.)($ ) − 1 ("" #$%./$ )
Formula 3.
>. >?@ = 1("" #$%&.)($ ) − 1("" #$%./$ )

Network rsFC: Group effects. To assess HIV and CB main and interactive effects
on the RAI we performed HIVxCB general linear models (GLMs) including age, sex, mean
FD, and whether the participant was a current cigarette smoker (NIC status; defined as
smoking at least 8 times in the last month) as covariates. We then examined whether group
differences in RAI were driven by altered SN-CEN rsFC or SN-DMN rsFC. Thus, we again
performed follow-up HIVxCB GLMs on participants’ standardized SN-L.CEN, SNR.CEN, and SN-DMN correlation coefficients (z-scores) while controlling for the same
covariates.
Network rsFC: Relation with immune system biomarkers. Then to explore links
between network rsFC and biomarkers of immune function we considered total plasma
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WBC count (thousand cells/uL), CD4+ T-cell count (cells/uL) and TNF-a levels among
PLWH in the study (n=54). PLWH were binned into two viral load groups (detectable
[>200 copies/mL] and undetectable [£ 200 copies/mL]) based on their copies of HIV-1
RNA/mL. To examine if viral load detectability status was moderating the relationship
between immune function and measures of network rsFC, we conducted immune function
x viral load (detectable vs. undetectable) ANCOVAs among PLWH with CB group
membership, age, sex, mean FD, and NIC status included as covariates. Follow-up
conditional effects, at each level of viral load, were assessed using the PROCESS v.5 SPSS
plugin [146] with the same covariates included.
Network rsFC: Relation with EAT behavior and brain activity. Then to examine
brain and behavior relationships across the full sample, we considered relationships
between network rsFC measures and a laboratory-based, behavioral measure of explicit
error awareness from the EAT. In the EAT, participants commit NoGo-errors (i.e.,
incorrectly press a button following a NoGo cue) of which they can be either aware or
unaware. Participants indicate error awareness by pressing an error signaling button. The
EAT allows for assessment of distinct brain activity linked with cognitive failures (i.e.,
NoGo-errors), and explicit error awareness. To achieve sufficient numbers of successful
and unsuccessful NoGo trials, task difficulty was individually and dynamically adapted to
maintain participants’ average NoGo-error rate between 45-50%. Subjects that did not
meet the task performance criterion (>50% Go-errors) were excluded resulting in a sample
of 103 participants that had viable task data and a sample of 86 participants that had both
viable task and rest data.
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We first assessed group effects on error awareness (frequency of unaware errors)
by performing an HIVxCB GLM with age, sex, and NIC status included as covariates
(n=103). Main and interaction effects were of interest. As the error awareness variable was
positively skewed and included zero values it was log10 transformed for this statistical test
and a constant was added (log10[x+1]). Additionally, we examined relationships between
network rsFC and error awareness. As frequency of unaware errors was a positively
skewed count variable and thus, did not meet assumptions required for linear regression
[276], we employed a negative binomial model (R, v.4.0.2) to statistically test these
relationships. Age, sex, mean FD, and NIC status were included as covariates in these
analyses. A negative binomial model was selected over a zero-inflated model or a Poisson
model as the formal test of dispersion indicated that the unware error count variable was
overdispersed (p’s<0.00013) [276].
We then considered EAT-related brain activity. Specifically, we assessed whether
responsivity to errors during the task, of the same networks examined in the rsFC analyses,
also presented HIVxCB effects and/or relationships with error awareness. The six EAT
runs were preprocessed and entered into a subject-level GLM including three task-related
regressors (NoGo-correct, NoGo-error, and Go-error]) as impulse functions time-locked to
stimulus onset and convolved with a hemodynamic response (gamma) function, and
nuisance regressors. Time series were scaled to the voxel-wise mean (3dcalc) thereby
allowing regression (b) coefficients, calculated per regressor and participant, to be
interpreted as an approximation of percent blood-oxygen-level-dependent (BOLD) signal
change (% BOLD D) [144] from the implicit baseline. Average b coefficients associated
with NoGo-error task events were extracted for each participant by averaging across all
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non-zero voxels within the four network masks. To assess group effects on error-related
network responsivity we conducted HIVxCB GLMs among participants that had viable
task data (n=103). Age, sex, and NIC status were included as covariates. Next, we
examined if error-related network responsivity predicted error awareness behavior by again
employing a negative binomial model among all participants that had both viable task and
rest data (n=86), while controlling for the same covariates. Finally, to better understand the
relationship between task-based network activation and network rsFC, we explored
relationships by performing partial Pearson’s correlations including, sex, age, and mean
FD during rest as covariates.

3.4. Results
Network rsFC: Group effects. A significant main effect of HIV-status was observed
on the resting-state RAI (Figure 1A) of both the right (F[1, 92]=7.5, p=0.008) and left
(F[1, 92]=4.3, p=0.042) hemisphere such that PLWH displayed significantly reduced RAI
when controlling for CB group membership, age, sex, mean FD, and NIC status (Figure
1B1). This HIV-associated alteration in RAI did not significantly differ among CB users
and nonusers as indicated by a nonsignificant HIVxCB interaction (right: F[1, 92]=0.01,
p=0.9; left: F[1, 92]=0.2, p=0.7) and nonsignificant CB main-effects (right: F[1, 92]=0.3,
p=0.6; left: F[1, 92]=0.4, p=0.5). Follow-up analyses suggest that this group difference was
primarily driven by PLWH displaying increased SN-DMN rsFC when compared to HIVcontrols (Figure 1B2; F[1, 92]=5.0, p=0.027). This HIV-associated alteration in SN-DMN
rsFC also appeared to be unaffected by CB use as indicated by nonsignificant HIVxCB
interaction (F[1, 92]=2.9, p=0.09) and CB main effects (F[1, 92]=0.2, p=0.6). However,
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visual inspection of SN-DMN rsFC across all four subject groups, and exploratory followup t-tests within each CB group, suggest that HIV group differences were most pronounced
when comparing nonuser groups (t[41]=-2.5, p=0.016), whereas there was relatively little
difference between the average SN-DMN rsFC of the co-occurring (HIV+ CB+) and CBonly (HIV-/CB+) groups (t[48]=-0.2, p=0.82). Both the right (Figure 1B3) and left SNCEN rsFC did not display any significant group differences (p’s>0.3). ICA-derived RAIs
and rsFC measures displayed HIV and CB group-effects with an equivalent directional
nature to those on atlas-derived RAI and rsFC measures (Figure S1B). A full description
of results from the ICA-based method are described in the supplemental text (Figure S12).

Figure 1. HIV main effect on network resource allocation and rsFC. (A) Depiction of
network resting-state functional connectivity (rsFC) differences between PLWH and HIV-
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participants. (B1) PLWH had a significantly reduced resource allocation index (RAI)
compared to HIV- participants for both the right (p=0.008) and left hemisphere (data not
displayed, F[1, 92]=4.3, p=0.042) when controlling for relevant covariates. (B2) Increased
SN-DMN rsFC among PLWH compared to HIV- participants (p=0.027). (B3) SN-R.CEN
and SN-L.CEN (data not displayed) rsFC did not significantly differ between HIV and CB
groups (p’s>0.3). Unstandardized residuals are plotted after regressing out effects of age,
sex, mean FD, and NIC status. Error bars = standard error of the mean.
Network rsFC: Relation with immune function/inflammation. Among the 54
PLWH in our sample, 14 had a detectable viral load (> 200 copies/mL). We observed a
significant WBC count by viral load interaction on resting-state RAI in the right
hemisphere (Figure 2A; F[1, 53]=5.3, p=0.026) such that, among those who had an
undetectable viral load (below 200 copies/mL), higher WBC counts were associated with
an increased RAI (t=3.02, p=0.004) when controlling for CB group membership, age, sex,
mean FD, and NIC status. Whereas, among those with a detectable viral load, WBC count
was not significantly related to RAI (t=-0.56, p=0.6). The WBC by viral load interaction
effect on the RAI in the left hemisphere displayed a similar pattern but did not reach
significance (F[1, 53]=3.9, p=0.054). Follow-up analyses on network rsFC suggest that this
interaction effect on RAI seems to be driven by a significant WBC count by viral load
interaction on SN-DMN rsFC (Figure 2B; F[1, 53]=6.3, p=0.016). Specifically, among
PLWH with an undetectable viral load, higher WBC counts were significantly associated
with reduced SN-DMN rsFC (t=-2.04, p=0.048) whereas, this relationship among those
with a detectable viral load again, did not reach significance (t=1.6, p=0.1). We did not
observe any significant effects of WBC count or viral load on right (Figure 2C) or left SNCEN rsFC (p‘s>0.8). Additionally, we did not observe any significant effects of CD4+ Tcell count (p’s>0.09) or TNF-a levels (p’s>0.1) on network connectivity measures.
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Figure 2. WBC count linked with network rsFC when viral load is undetectable. (A)
Significant WBC x viral load interaction on the right resource allocation index (RAI; F[1,
53]=5.3, p=0.026) and (B) salience network (SN)-default mode network (DMN) restingstate connectivity (rsFC; F[1, 53]=6.3, p=0.016). Follow-up conditional effects assessed
within each viral load group indicated that, among PLWH that had an undetectable viral
load (< 200 HIV RNA copies/mL; n=40; purple), increased WBC count was associated
with both an increased RAI in the right hemisphere (t=3.02, p=0.004) and decreased SNDMN rsFC (t=-2.04, p=0.048). Whereas, among PLWH that had a detectable viral load (>
200 HIV RNA copies/mL; n=14; orange), these relationships were not significant
(p’s>0.1). (C) WBC count was not significantly associated with SN-R.CEN rsFC or L.CEN
(data not shown). Unstandardized residuals are plotted after regressing out effects of age,
sex, mean FD, and NIC status.
Network rsFC: Relation with error awareness and error-related network activity.
We observed a significant HIVxCB interaction on our behavioral measure of error
awareness (F[1, 102]=4.7, p=0.03) after controlling for covariates (Figure 3A).
Specifically, both the HIV-only (HIV+/CB-) and CB-only (HIV-/CB+) groups committed
more unaware errors, compared to controls, whereas the co-occurring (HIV+/CB+) group
had a lower frequency of unaware errors more similar to that of controls. Additionally,
negative binomial models examining relations between network rsFC and error awareness
indicated that, when controlling for covariates, increased SN-DMN rsFC was associated
with reduced error awareness (more unaware errors; Figure 3B; b=2.0 [0.8], z=2.5,
p=0.01). Both right and left SN-CEN rsFC did not display a significant relationship with
error awareness (p’s>0.3).
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When examining error-related b coefficients from the EAT, averaged across voxels
in each network (DMN, SN, R.CEN, L.CEN), we observed a significant main effect of
HIV, such that PLWH had significantly higher average error-related DMN activity than
HIV- participants (F[1, 102]=5.1, p=0.026; Figure 4A). This increased DMN responsivity
to errors among PLHW was not impacted by CB use, as indicated by the insignificant
HIVxCB interaction effect (F[1, 102]=0.3, p=0.9). Error-related R.CEN, L.CEN, and SN
activity did not differ between HIV groups (p’s>0.4) or show any other significant group
effects (p’s>0.3). Interestingly, increased error-related activity in both, the right (b=-0.5
[0.2], z=-2.2, p=0.025), and left (b=-0.4 [0.2], z=-2.0, p=0.047) CEN was significantly
associated with improved error awareness (reduced unaware errors) (Figure 4B).
However, error-related activity in the DMN (b=-0.3 [0.2], z=-1.6, p=0.1) and SN (b=-0.2
[0.2], z=-0.8, p=0.4) was not significantly associated with error awareness. Finally, when
controlling for HIV group membership, CB group membership, sex, age, mean FD (during
resting-state), and NIC status, we did not observe any significant relationships between
network rsFC (SN-DMN, SN-CEN) and task-based, error-related activity in these networks
(p’s>0.4).
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Figure 3. SN-DMN rsFC linked with error awareness. (A) Significant HIVxCB
interaction (F[1, 102]=4.7, p=0.03) on error awareness (operationalized as the log
transformed number of unaware errors (log10[x+1]); constant added to address zero values)
while controlling for sex, age, and cigarette smoking (NIC) status (n=103) such that, when
compared to controls, both the HIV-only (HIV+/CB-) and CB-only (HIV-/CB+) groups
committed more unaware errors, whereas the co-occurring (HIV+/CB+) group had a lower
frequency of unaware errors more similar to that of controls. (B) Increased salience
network (SN)-default mode network (DMN) resting-state functional connectivity (rsFC)
was significantly associated with increased unaware errors (negative binomial model
[n=86]: b=2.0 [0.8], z=2.5, p=0.011). Contrarily, SN rsFC with both the left (data not
shown: b=0.7 [0.8], z=0.9, p=0.3) and right central executive network (CEN; b=0.8 [0.8],
z=1.0, p=0.3) was not significantly associated with error awareness. Unstandardized
residuals are plotted after regressing out effects of covariates. Error bars = standard error
of the mean.
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Figure 4. Error-related network activity and relationships with error awareness. (A)
HIVxCB general linear model (GLM) assessing group-effects on error-related network
responsivity (average b coefficients associated with NoGo-error task events for each
network) while controlling for sex, age, and cigarette smoking (NIC) status among all
participants with viable task data (n=103). People living with HIV (PLWH) had
significantly higher error-related default mode network (DMN) activity than HIVparticipants (F[1, 102]=5.1, p=0.026). Error-related right central executive network
(R.CEN), left CEN (L.CEN), and saliency network (SN) activity did not differ between
HIV groups (p’s>0.3). (B) Increased error-related R.CEN responsivity was significantly
associated with higher error awareness (negative binomial model [n=103]: b=-0.5 [0.2],
z=-2.2, p=0.025) while controlling for sex, age, and cigarette smoking (NIC) status. A
similar relationship was observed for error-related L.CEN responsivity (data not shown:
b=-0.4 [0.2], z=-2.0, p=0.047). However, both error-related DMN (b=-0.3 [0.2], z=-1.6,
p=0.1) and SN (b=-0.2 [0.2], z=-0.8, p=0.4) responsivity was not significantly associated
with error awareness. Unstandardized residuals are plotted after regressing out effects of
covariates. Error bars = standard error of the mean.
3.5. Discussion
We observed bilaterally reduced RAIs among PLWH driven by increased SNDMN rsFC whereas, SN-CEN rsFC was not significantly different across groups. Both
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decreased RAI and increased SN-DMN rsFC were linked to a biomarker of compromised
immune function (reduced total WBC counts) among virally undetectable PLWH
indicating that HIV’s impact on network function may vary in a graded fashion depending
on certain characteristics of disease severity. Further, results indicated that intrinsic SNDMN interactions during rest may have implications for DMN suppression during error
processing and error awareness. Specifically, increased SN-DMN synchrony was
associated with reduced error awareness. Additionally, while SN-DMN rsFC was not
correlated with error-related DMN suppression, PLWH displayed reduced error-related
DMN suppression compared to HIV- controls. These results demonstrate a pattern of
dysregulated network function among PLWH, that is also common across a multitude of
substance use and neurodegenerative disorders [62, 111-119, 258-269], and begin to
illuminate implications for critical error awareness mechanisms.
Reduced RAI among PLWH. The RAI has previously been used to examine the
degree of dysfunction in large-scale network interactions. This index aims to represent the
synchrony of the SN with the CEN, a brain network supporting attention on external
stimuli, relative to its synchrony with the DMN, a network supporting attention on
internally invoked thoughts. We observed that PLWH had bilaterally reduced RAIs, when
compared to HIV- participants, similar to observations among nicotine and other drug
dependent individuals in acute withdrawal [250, 275]. Many of the cognitive deficits
characterizing nicotine withdrawal are hypothesized to stem from an inability to suppress
attention toward internal craving and aversive somatic withdrawal symptoms [62, 250,
277-279]. Our results may point toward a similar mechanism at play among PLWH that
could account for certain cognitive deficits that persist in the post-ART era. Specifically,
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deficits reported in learning, memory, and performance on cognitive tasks involving
executive function, may be manifestations of a more general attentional impairment
characterized by an inability to suppress attention toward physical and/or emotional HIV
symptomology.
Increased SN-DMN rsFC among PLWH. This interpretation is further supported
by our observation that the HIV-associated RAI reduction was primarily driven by PLWH
having higher SN-DMN synchrony than controls while SN-CEN synchrony did not
significantly differ between groups. These findings are consistent with prior work among
individuals living with multiple sclerosis (MS), which, like HIV, leads to chronic
inflammation in the CNS. Specifically, people living with MS displayed increased DMN
rsFC to regions comprising the SN and these rsFC increases were associated with symptom
severity [264, 265]. Additionally, altered rsFC of the DMN has been wildly linked with
AD [280, 281] and other degenerative disorders [258-260]. Specifically, emerging
evidence suggests that the mild cognitive declines preceding the onset and progressive
deterioration of AD may be associated with an initial increase in DMN rsFC that is
followed by later rsFC decreases [261, 280, 281]. Accordingly, other research suggests that
changes

in

DMN

rsFC

may

predict

future

cognitive

impairments

before

neuropsychological performance falls outside the normal range. Specifically, one study
found that, among individuals with a family history of AD, early subjective cognitive
decline, is associated with increased rsFC between the DMN and regions making-up the
medial temporal memory system [263]. Another study observed that individuals with mild
cognitive impairments and those reporting cognitive complaints, despite normal
neuropsychological performance, display decreased rsFC between the DMN and right
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hippocampus compared to age-matched controls [262]. This prior work suggests that mild
cognitive impairments characterizing the early phases of degenerative inflammatory
diseases may be linked with similar alterations in large-scale network interactions as
cognitive deficits persisting among PLWH in the post-ART era. Future longitudinal
examinations of changes in DMN rsFC across HIV disease phases may shed light on
potentially, nonlinear relationships between severity of cognitive decline and DMN rsFC
changes that mirror findings among AD patients [261, 280, 281].
Relation with WBC count. Our exploratory examination of biomarkers denoting
aspects of immune system function among PLWH provide an initial indication that
observed alterations in intrinsic network interactions may be graded across varying degrees
of immune health, but will require additional, longitudinal examinations to be fully
understood. Most of our participants living with HIV (74.1%) had an undetectable viral
load (below 200 copies/mL), which is becoming the norm in the post-ART era [282, 283].
Our results indicated that among these participants with an undetectable viral load,
diminished WBC counts were associated with increasingly larger deviations of both RAI
and SN-DMN rsFC from that of controls (lower RAI and higher SN-DMN rsFC).
However, we did not observe this same relationship among participants with a detectable
viral load. This may be due to high viral loads both killing WBCs, and signaling acute
immune system activation resulting in more unpredictable spikes and dips in total WBC
count. Further, we did not observe any significant relationships between measures of
intrinsic network interactions and CD4+ T-cell count or TNF-a levels.
Increased inflammatory cytokines in the blood of PLWH, are thought to contribute
to brain inflammation and play a major role in HIV-associated cognitive symptoms [79].
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Additionally, HIV injures the immune system by targeting and killing CD4+ T cells as well
as other types of WBCs [284]. However, the balance between HIV’s destruction of the
immune system and the immune system’s defensive response to the virus has shown to be
a prolonged, complicated, and dynamic interaction, especially in the context of ART [285].
Further complications include, the various influences on, and responsivity of, lymphocyte
subtypes. Consequently, our measurement of total WBCs, in the periphery blood, weeks
before fMRI data collection, is a relatively crude measure of how the immune system is
fairing with respect to current HIV viral load. Our observed viral load by WBC count
interaction on intrinsic network connectivity among PLWH cannot speak to mechanistic
avenues through which the immune system may be influencing brain function in PLWH,
but merely motivates more comprehensive quantifications of immune system function
across the course of disease progression that can better characterize how immune dynamics
within subject may lead to altered brain network operations. While more work is needed
to clarify the exact disease mechanisms by which the HIV infection is impacting brain
function, these results support other work suggesting that certain aspects of immune system
function may mediate HIV effects on the brain [286-288].
Normalizing effect of CB among PLWH. Interestingly, while we did not observe a
significant HIVxCB interaction on RAI or SN-DMN rsFC, visual inspection of each
subject groups’ average SN-DMN rsFC, and exploratory follow-up t-tests, indicated that
HIV group differences were most pronounced in nonuser groups, whereas there was
relatively little difference between the CB using HIV+ and HIV- groups’ average SN-DMN
rsFC. Among HIV- participants, chronic CB use was associated with increased SN-DMN
rsFC compared to nonusers, congruent with prior hypotheses of addiction pathology [250-
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253]. SN-DMN rsFC was highest among the HIV+ non-using group however, CB use
among PLWH seemed to protect against an additional SN-DMN increase. Further, we
observed a similar, significant HIVxCB interaction on our behavioral measure of error
awareness after controlling for covariates. Specifically, both the HIV-only (HIV+/CB-)
and CB-only (HIV-/CB+) groups displayed diminished error awareness compared to
controls, whereas the co-occurring (HIV+/CB+) group had error awareness more akin to
that of controls. These results may corroborate prior observations of CB partially
normalizing HIV-associated brain function abnormalities and provides extended evidence
of a similar normalizing effect on behavioral performance [51, 52].
Increased SN-DMN rsFC linked with poor error-awareness. The DMN is thought
to be active during task-unrelated mind-wandering and deactivated during task-on attention
[106]. Additionally, suppression of the DMN during tasks is thought to support task
vigilance and detection of salient stimuli [109]. Consequently, DMN suppression is likely
also vital for error recognition. There is evidence to suggest that DMN rsFC is also linked
to levels of attentiveness as disorders characterized by attentional problems specifically,
attention deficit hyperactivity disorder (ADHD) [269] and internet gaming disorder [268]
are associated with increased rsFC between the DMN and regions comprising the SN.
Correspondingly, we observed that heightened intrinsic SN-DMN synchrony during rest is
associated with diminished error awareness. These results suggest that network interaction
tendencies during rest may have implications for error-monitoring during tasks and link
the increased SN-DMN synchrony, observed among PLWH, to the diminished error
awareness that was displayed by non-using PLWH (HIV+/CB-) relative to their HIVcounterparts (HIV-/CB-).
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Task-based network responsivity to errors. A lack of appropriate trial-by-trial DMN
suppression during tasks, has been repeatedly associated with various neurocognitive
disorders [111-113] including major depressive disorder [114], schizophrenia [115],
addiction [62, 116, 117] and ADHD [118, 119]. We extend these findings, demonstrating
significantly reduced DMN suppression during errors among PLWH. A robust body of
work has shown that task-based DMN suppression plays a critical role in monitoring taskstimuli [164] and is related to increasing cognitive demands [106, 110] and task
performance [107, 108]. Given our finding that SN-DMN rsFC was both heightened among
PLWH, and associated with poor error awareness, we expected that this reduced DMN
suppression during errors, that was displayed among PLWH, would similarly be related to
error awareness; however, we did not observe a significant association between DMN error
suppression and error awareness. Although, we did find that increased bilateral CEN errorresponsivity was significantly associated with improved error awareness. Future research
is needed to fully understand the relationship between reduced error-related DMN
suppression among PLWH and impaired error awareness.
While research has shown that properties of functional networks identified during
rest reflect a similar functional network architecture at play during tasks, it still remains
unclear how the two are related [272]. To more fully understand altered network
organization among PLWH we examined relationships between rsFC between large-scale
networks and network responsivity to task events. We did not observe a relationship
between measures of network function during rest and task. While task data was collected
during the same scan session (1.5hr) as rest data, the observed lack of correlation between
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the two may, to some degree, be influenced by a lack of within subject reliability/stability
across scans that has been reported previously [289].
Limitations. Our approach to calculating the RAI facilitated interpretation of results
with respect to prior work [62, 250] however, the following limitations should be
considered. First, recent work by Moradi and colleagues [72] has highlighted the
significance of network mask definition procedure in the calculation of RAI. Specifically,
while their group-average ICA on the rsFC of their sample resulted in right and left CEN
masks that closely matched the CEN masks used herein [273], it also dissociated RAIs
calculated using two different SN masks and three different DMN masks whereas the
current manuscript only considered one network mask for the DMN and one for the SN.
As comparing the RAIs calculated with every possible combination of network masks
included in Moradi and colleagues paper (>20 RAIs), was beyond the scope of the current
work, we utilized network mask definitions that included all hub regions of interest (PCC,
medial prefrontal cortex, and hippocampus in the DMN; anterior insula, anterior cingulate
cortex, and sensorimotor areas in the SN) given our own prior findings and the existing
HIV neuroimaging literature [14, 51, 53]. As our analyses aimed to capture brain function
at a large-scale, network-level, examining differences between RAIs and rsFC coefficients
driven

by regional- and voxel-level

discrepancies between

varying network

operationalizations, was not of primary interest. However, our results should be interpreted
accordingly, and future research examining how variation across network definitions
impacts HIV-associated alterations in network functional interactions is warranted.
Second, our null effects regarding the correlation between network rsFC strength and taskbased network error responsivity may have been unpredictably influenced by controlling
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for the average FD during rest. We controlled for mean FD of the resting-state scan as head
motion was likely greater during rest than task and head motion is known to influence
measures of BOLD activity. More work is needed to understand within-subject
relationships between rsFC and task-based brain function and should consider exploring
best-practices for controlling for head motion in these analyses.
Conclusions. Our results demonstrate increased SN-DMN rsFC and reduced errorrelated DMN suppression linked with HIV serostatus. These findings demonstrate a pattern
of dysregulated network function, present during both rest and task, and seen across
multiple neurocognitive conditions, that may contribute to cognitive deficits commonly
associated with HIV in the post-ART era. Further, we critically linked these HIVassociated alterations in intrinsic network interactions with impaired error awareness that
was displayed among non-using PLWH and HIV- CB users, but importantly normalized
among CB using PLWH.
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CONCLUSION
People living with HIV (PLWH), compared to HIV- participants, displayed a lack
of error-related deactivation in two default mode network (DMN) regions, the posterior
cingulate cortex (PCC) and the medial prefrontal cortex (mPFC). Reduced error-related
PCC deactivation correlated with reduced medication management abilities across all
participants, and mediated the effect of HIV on such abilities. While, no cannabis (CB)
main or interaction effects were detected, more lifetime CB use was linked with reduced
error-related mPFC deactivation among HIV- participants and poorer medication
management across CB users. Regarding insular circuitry, we observed interactive
HIVxCB effects on rsFC between two anterior insula (aI) subregions and sensorimotor
cortices such that, CB use appeared to normalize altered rsFC that was observed among
non-using PLWH. Specifically, compared to controls, HIV-only and CB-only groups
displayed decreased dorsal anterior insula (DI) - postcentral gyrus rsFC and increased
ventral anterior insula (VI) - supplementary motor area (SMA) rsFC whereas, the cooccurring HIV+/CB+ group displayed DI and VI rsFC more akin to that of controls.
Interestingly, altered DI - postcentral gyrus rsFC correlated with decreased somatic
complaints across all participants and increased circulating levels of TNF-α among PLWH.
Finally, at a systems-level, PLWH displayed increased SN-DMN rsFC that was associated
with reduced total white blood cell (WBC) counts among virally undetectable PLWH and
diminished error-awareness across all participants.
These findings suggest that PLWH present a pattern of altered DMN activity which
is discernable at both a regional (task-based) and systems-level (resting state). Importantly,
such altered DMN functioning may contribute to impairments in error-processing and real-
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world medication management abilities. Given robust evidence linking both disrupted
DMN suppression and DMN connectivity patterns with reduced attention toward external
stimuli [106-110, 112, 290-292], we posit that certain HIV and CB-associated
neurocognitive alterations may stem from a reduced ability to disengage task irreverent
mental operations that ultimately hinders cognitive control, error monitoring, and behavior
modification. As insufficient DMN suppression and elevated SN-DMN synchrony are
common endophenotypes across various neuropsychiatric conditions [62, 111-119], but
have not previously been associated with HIV, these results provide a useful connection
between the neurocognitive mechanisms of HIV-associated cognitive impairments and
those of various other conditions. Additionally, delineating this cognitive neuroscience
mechanism in the context of HIV infection and CB use may provide heuristic value for
strategies to improve medication adherence.
Our findings also support and extend prior work, highlighting disruptions in insula
- sensorimotor neurocircuitries that may be of particular importance when assessing the
interactive impact of HIV and CB on inflammation and brain function. While prior work
has demonstrated CB use potentially normalizing alterations in large-scale brain network
organization observed among PLWH, the cognitive implications of this observation
remained unknown [52]. Our observation of a similar CB-related normalization of insulacentric rsFC among PLWH extends this former research by identifying specific insula sensorimotor neurocircuitries and delineating rsFC relationships with measures of
inflammation. Given the anti-inflammatory properties of CB [183, 184] and prior work
linking insula function to inflammatory responses [55, 56], our results begin to elucidate
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potential inflammatory mechanisms through which CB use may impact brain function in
the context of HIV.
Overall, this work identifies two important neurocognitive mechanisms that may
underlie behavioral alterations among PLWH, namely insufficient DMN downregulation,
that may have specific implications for error monitoring and medication management and
altered aI - sensorimotor cortex rsFC, that is associated with inflammation. While we did
not observe additive or interacting impacts of CB use on HIV-associated alterations in
DMN function during error-processing or rest, we did observe a normalizing effect of CB
use on aI rsFC alterations among PLWH. This dissociation further demonstrates the
complicated nature by which CB use may further impact some, but not all, functional brain
alterations associated with HIV. These results pave the way for future work to examine
potential anti-inflammatory mechanisms through which CB may act on specific HIVassociated alterations in brain function with important implications for everyday
functioning and disease management behaviors.
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APPENDICES
Appendix 1: Supplemental Material for Chapter 1
Table S1. Participant mental health status by group: Sample with task-based data.
Group Effects
(p’s)
HIV
CB

All
Participants
n=109

HIV+/CB+
n=32

HIV+/CBn=27

HIV-/CB+
n=28

HIV-/CBn=22

12

4

3

2

3

0.8

0.7

25

11

3

4

7

0.8

0.6

Major Depressive
Episode (current)
Major Depressive
Episode (past)

NOTE. Mental health status is reported as count of participants meeting criteria for a
current or past Major depressive episode as assessed via the Structured Clinical Interview
for DSM-5 Research Version (SCID-5-RV). Participants were excluded from the sample
if they presented severe mental illnesses with psychotic or paranoid symptoms. Group
effects were assessed with two Chi-square tests, one comparing the HIV+ versus HIVgroups and the other comparing the CB+ versus CB- groups. No group differences were
detected for any measure when conducting these same analyses after excluding participants
who did not meet task engagement quality control threshold (n=2: HIV+/CB+; n=2:
HIV+/CB-; n=2: HIV-/CB+).
Table S2. HIV status and immune system markers: Sample with task-based data
All HIV+
Participants
n=59

HIV+/CB+
n=32

HIV+/CBn=27

Group Effects
(p’s)

9.8 (9.2)

8.7 (8.1)

11.1 (10.3)

0.3

64.4

62.5

66.7

0.6

13.6

15.6

11.1

0.6

8,673.3
(37,628.1)
1.1 (1.5)

Disease Characteristics
Years since HIV diagnosis
% with detectable viral load
(>200 copies/mL)
% with AIDS diagnosis
Viral Load (copies of HIV RNA/mL)
HIV-1 (Linear)

14,087.1 (54,905.1)

HIV-1 (Log10)

1.3 (1.7)

18,654.9
(66,374.6)
1.4 (1.8)

T Helper Cells (CD3+CD4+)

639.0 (304.4)

647.6 (275.3)

628.9 (340.9)

0.8

T Suppress./Cyt.(CD3+CB8+)

1,064.8 (552.3)

972.2 (426.0)

1,174.5 (664.1)

0.8

0.2
0.2

Lymphocyte Subsets (cells/uL)

NOTE. Data are either expressed as mean (standard deviation) or as the percentage of
participants. HIV-1 viral load assessed via the Abbott RealTime HIV-1 assay. Group
effects were assessed with independent samples t-tests or Chi-square tests comparing HIV+
cannabis users versus nonusers. No group differences were detected for any measure when

129

conducting these same analyses after excluding participants who did not meet task
engagement quality control threshold (n=2: HIV+/CB+ and n=2: HIV+/CB-).
Table S3. Participant plasma THC levels by group: Sample with task-based data

9-carboxy-THC (ng/mL)

All CB+ Participants
n=60
717.3 (1,087.1)

HIV+/CB+
n=32
853.1 (1,343.9)

HIV-/CB+
n =28
562.1 (679.7)

Group Effects
(p’s)
0.3

596.8 (686.9)

592.0 (712.0)

602.6 (670.0)

0.9

THC/creatinine ratio (ng/mg)

NOTE. Data are expressed as mean (standard deviation). Group effects were assessed with
an independent samples t-test comparing cannabis using participants that were HIV+
versus HIV-. No group differences were detected for any measure when conducting these
same analyses after excluding the participant who did not meet task engagement quality
control threshold (n=2: HIV+/CB+ and n=2: HIV-/CB+).
Table S4. Drug dependence status by group: Sample with task-based data.

% Cannabis (past
month)
% Cannabis
(lifetime)
% Alcohol
(lifetime)
% Cocaine
(lifetime)
% Other stimulants
(lifetime)
% Opiates
(lifetime)
% Other sedatives
(lifetime)
% Hallucinogens
(lifetime)
% Other drug
(lifetime)

Group Effects
(p’s)
HIV
CB

All
Participants
n=109

HIV+/CB+
n=32

HIV+/CBn=27

HIV-/CB+
n=28

HIV-/CBn=22

10.1

18.8

0

17.9

0

0.9

0.002

18.3

25.0

3.7

35.7

4.5

0.4

<0.001

11.9

9.4

7.4

17.9

13.6

0.2

0.6

11.0

9.4

7.4

14.3

13.6

0.4

0.8

3.7

9.4

3.7

0

0

-

-

1.8

3.1

0

3.6

0

-

-

1.8

6.3

0

0

0

-

-

1.8

6.3

0

0

0

-

-

1.8

3.1

0

3.6

0

-

-

NOTE. Drug dependence data are expressed as the percentage of participants meeting
dependency criteria either ever (lifetime) or in the past month (past month), as defined in
the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV). As current
(past month) drug dependence was exclusionary criteria (except cannabis dependence in
the CB+ groups), no participants met dependency criteria in the past month for any of the
reported drugs. Group effects were assessed with two Chi-square tests, one comparing the
HIV+ vs. HIV- groups and one comparing the CB+ vs. CB- groups. These analyses were
not performed when data did not meet criteria for Chi-square tests (cells with <5
observations). No significant differences were detected for any measure when conducting
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these same analyses after excluding participants who did not meet task engagement quality
control threshold (n=2: HIV+/CB+; n=2: HIV+/CB-; n=2: HIV-/CB+).
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Table S5. Past month and lifetime drug use: Sample with task-based data.

Cannabis (past
month)
Cannabis
(lifetime)
Alcohol (past
month)
Alcohol (lifetime)
Cocaine (past
month)
Cocaine
(lifetime)
Nicotine (past
month)
Nicotine
(lifetime)
Methamphetamin
e (past month)
Methamphetamin
e (lifetime)
Prescription
stimulants (past
month)
Prescription
stimulants
(lifetime)
Heroin (past
month)
Heroin (lifetime)
Opiates (past
month)
Opiates (lifetime)
Benzodiazepines
(past month)

All Participants
n=109

HIV+/CB+
n=32

HIV+/CBn=27

HIV-/CB+
n=28

HIV-/CBn=22

13.0 (14.0)

21.9 (10.7)

0

25.6 (9.2)

2,404.7 (3,356.9)

3,765.6 (3,488.9)

114.0 (427.7)

2.3 (3.6)

2.2 (2.7)

1,204.7 (1,644.2)

Group Effects
HIVxCB

HIV

CB

0

p=0.2

p=0.2

p<0.001*

4,580.3 (3,733.1)

467.5 (1,423.3)

p=0.7

p=0.3

p<0.001*

2.1 (4.1)

3.3 (4.6)

1.6 (2.7)

p=0.2

p=0.7

p=0.2

1,198.5 (1,634.7)

1,184.8 (1,689.7)

1,416.1 (1,537.1)

969.2 (1,807.6)

p=0.5

p=0.9

p=0.5

0.0 (0.1)

0.1 (0.2)

0

0

0

p=0.2

p=0.2

p=0.2

362.5 (1,186.0)

351.0 (1,021.0)

297.9 (1,026.4)

312.0 (833.0)

523.0 (1,860.8)

p=0.6

p=0.7

p=0.7

5.5 (11.3)

8.2 (13.3)

0.3 (1.5)

7.9 (13.1)

4.9 (10.8)

p=0.3

p=0.3

p=0.012*

2,081.9 (3,731.2)

2,765.7 (4,542.0)

981.1 (2,540.5)

2,366.3 (3,328.6)

2,076.3 (4,065.8)

p=0.3

p=0.6

p=0.2

0.0 (0.2)

0.1 (0.4)

0

0

0

p=0.4

p=0.4

p=0.4

25.0 (126.6)

52.7 (208.8)

27.6 (99.3)

10.4 (54.4)

0.05 (0.2)

p=0.8

p=0.2

p=0.5

0.02 (0.2)

0

0

0.1 (0.4)

0

p=0.3

p=0.3

p=0.3

22.7 (207.2)

72.8 (381.4)

0

5.2 (22.7)

0

p=0.4

p=0.4

p=0.3

0

0

0

0

0

-

-

-

6.6 (69.0)

0

0

25.8 (136.1)

0.05 (0.2)

p=0.3

p=0.3

p=0.3

0

0

0

0 (0.2)

0

-

-

-

17.8 (102.6)

25.8 (127.2)

0

39.3 (149.7)

0.6 (2.5)

p=0.7

p=0.7

p=0.1

0

0

0

0.04 (0.2)

0

p=0.3

p=0.3

p=0.3
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Benzodiazepines
(lifetime)
Barbiturates (past
month)
Barbiturates
(lifetime)
Ecstasy (past
month)
Ecstasy (lifetime)
Inhalants (past
month)
Inhalants
(lifetime)
Ever injection
drug use (count)

34.1 (252.7)

112.9 (461.9)

0

2.9 (7.3)

1.1 (3.6)

p=0.3

p=0.3

p=0.2

0

0

0

0

0

-

-

-

6.5 (47.9)

22.1 (87.4)

0

0.04 (0.2)

0

p=0.2

p=0.2

p=0.2

0

0

0

0

0

-

-

-

27.6 (93.5)

59.3 (147.9)

0.5 (1.6)

39.1 (84.6)

0.1 (0.4)

p=0.6

p=0.6

p=0.007*

0.04 (0.3)

0.1 (0.5)

0

0

0

p=0.2

p=0.2

p=0.2

3.4 (17.0)

57.2 (166.1)

0.2 (1.0)

2.5 (12.3)

0

p=0.1

p=0.1

p=0.1

2

1

0

1

0

-

p=0.4

p=0.4

NOTE. Data are expressed as mean (standard deviation). Drug use was self-reported as the number of “times” using each drug in
the given timeframe (past month or lifetime) via items selected from the National Survey on Drug Use and Health. Group effects
were assessed with either an HIVxCB ANOVA or Chi square tests. * p < 0.05. No significant differences were detected for any
measure when conducting these same analyses after excluding participants who did not meet task engagement quality control
threshold (n=2: HIV+/CB+; n=2: HIV+/CB-; n=2: HIV-/CB+).
Table S6. EAT trial type counts and percentages by sample (n=109, 103, or 86).
Trial Type Count
a)
b)
c)

n=109

n=103

n=86

Mean ± SEM

Range

Mean ± SEM

Range

Mean ± SEM

Range

Go-correct

904.4 ± 15.6

275-1056

936.6 ± 9.3

588-1056

929.3 ± 10.9

588-1056

Go-error-omission

63.5 ± 14.7

0-720

29.2 ± 5.4

0-313

34.4 ± 6.3

0-313

NoGo-correct

115.7 ± 3.1

29-198

114.4 ± 3.1

29-198

114.6 ± 3.6

0-313

NoGo-error (commission)

97.3 ± 3.3

18-187

98.5 ± 3.2

18-187

97.7 ± 3.7

18-187

NoGo-error-aware

69.2 ± 3.1

0-134

71.9 ± 3.1

0-134

70.2 ± 3.2

3-122

NoGo-error-unaware

21.1 ± 2.5

0-148

20.9 ± 2.6

0-148

21.2 ± 2.3

3-97

NoGo-error no response

7.0 ± 1.4

0-123

5.8 ± 0.8

0-60

6.2 ± 0.9

0-60
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d)

e)

40.7 ± 1.8

8-94

40.9 ± 1.8

8-94

41.6 ± 2.0

8-94

NoGo-repeat-error-aware

24.9 ± 1.4

0-60

25.7 ± 1.4

0-60

25.2 ± 1.5

0-56

NoGo-repeat-error-unaware

12.5 ± 1.5

0-80

12.4 ± 1.6

0-80

13.3 ± 1.7

0-80

NoGo-repeat-error no response

3.3 ± 0.7

0-58

2.8 ± 0.4

0-34

3.1 ± 0.5

0-34

NoGo-repeat-error

56.7± 1.9

10-99

57.6 ± 1.9

10-99

56.0 ± 2.2

10-99

NoGo-Stroop-error-aware

44.3 ± 2.0

0-82

46.2 ± 1.9

0-82

45.0 ± 2.0

2-82

NoGo-Stroop-error-unaware

8.6 ± 1.2

0-82

8.4 ± 1.3

0-82

8.0 ± 1.0

0-51

NoGo-Stroop-error no response

3.7 ± 0.7

0-65

3.0 ± 0.4

0-26

3.1 ± 0.4

0-26

NoGo-Stroop-error

Trial Type Percent
a)
b)
c)

d)

e)

n=109

n=103

n=86

% Go-correct

Mean ± SEM
93.5 ± 1.5

Range
30.1-100

Mean ± SEM
96.9 ± 0.6

Range
65.3-100

Mean ± SEM
96.4 ± 6.2

Range
65.3-100

% Go-error-omission

6.5 ± 1.5

0-69.9

3.1 ± 0.6

0-34.7

3.7 ± 0.7

0-34.7

% NoGo-correct

54.5 ± 1.5

13.4-91.7

53.9 ± 1.5

13.4-91.7

54.2 ± 1.7

13.4-91.7

% NoGo-error (commission)

45.6 ± 1.5

8.3-86.6

46.1 ± 1.5

8.3-86.6

45.8 ± 1.7

8.3-86.6

% NoGo-error-aware

72.0 ± 2.5

0-100

73.5 ± 2.4

0-100

72.5 ± 2.3

3.2-96.9

% NoGo-error-unaware

21.7 ± 2.3

0-100

21.2 ± 2.3

0-100

21.8 ± 2.2

2.4-86.3

% NoGo-error no response

6.3 ± 0.9

0-74.1

5.4 ± 0.7

0-33.5

5.8 ± 0.7

0-33.5

% NoGo-repeat-error

41.4 ± 1.6

9.8-74.6

40.9 ± 1.0

19.8-74.6

42.1 ± 1.0

21.6-74.6

% NoGo-repeat-error-aware

64.6 ± 2.8

0-100

65.6 ± 2.8

0-100

63.1 ± 2.8

0-97.6

% NoGo-repeat-error-unaware

28.8 ± 2.7

0-100

28.6 ± 2.8

0-100

30.6 ± 2.8

0-97.6

% NoGo-repeat-error no response

6.6 ± 1.0

0-77.3

5.8 ± 0.7

0-42.5

6.3 ± 0.3

0-42.5

58.6 ± 1.7

25.4-80.2

59.1 ± 1.0

25.4-80.2

57.9 ± 1.0

25.4-78.4

% NoGo-Stroop-error-aware

77.6 ± 2.4

0-100

79.3 ± 2.3

0-100

79.5 ± 2.1

12.5-100

% NoGo-Stroop-error-unaware

16.2 ± 2.1

0-100

15.5 ± 2.1

0-100

15.0 ± 1.8

0-75

% NoGo-Stroop-error no response

6.2 ± 0.9

0-71.4

5.2 ± 0.7

0-39.3

5.5 ± 0.7

0-39.3

% NoGo-Stroop-error

NOTE. The n=103 sample was used for error-related brain and behavior assessments and excluded 6 participants from the total
sample (n=109) that did not meet task performance criteria (more than 50% Go-errors). The n=86 sample was used for errorawareness-related brain and behavior assessments and excluded an additional 17 participants that did not commit at least 2 of each
type of NoGo-error (aware and unaware). Trial Type Count: Rows in section a) do not add up to 1080 total Go trails because for
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every incorrect NoGo trial, an Awareness-trial, in which participants are instructed to press button-2 to indicate error awareness,
takes the place of the Go trial immediately following the error. Further, four subjects only completed 4 out of the 6 task runs (720
total Go trails and 144 total NoGo trials) and one subject only completed 5 out of the 6 task runs (900 total Go trials and 180 total
NoGo trials). This is also why rows in section b) do not add up to 216 total NoGo trials. Trial Type Percent: This section reports
the a) percentage of correct and error Go trails out of total Go trials (adds up to 100%) and b) the percentage of correct and error
NoGo trials out of the total NoGo trials (adds up to 100%). c) The percentage of aware, unaware and no response NoGo-errors out
of all NoGo-errors (adds up to 100%). d-e) NoGo-repeat-errors and NoGo-Stroop-errors out of all NoGo errors (values italicized)
such that these italicized values add up to 100%.
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Table S7. Cognitive control success and failure cluster coordinates.

Region

Hemisphere

Center
Coordinates
(MNI, LPI)
X
Y
Z

Cluster Size
(# of Voxels)

NoGo-Correct (C > E)
1

Middle occipital gyrus

R

32

-79

15

625

2

Middle occipital gyrus

L

-29

-85

13

564

3

Cerebral white matter
Ventral striatum (putamen,
nucleus accumbens)
Paracentral gyrus (primary
motor cortex, primary sensory
cortex)
Superior temporal gyrus
Ventral striatum (putamen,
nucleus accumbens)
Paracentral gyrus (primary
motor cortex, primary sensory
cortex)
Hippocampus
(parahippocampus, amygdala)
Cerebral white matter
Hippocampus
(parahippocampus, amygdala)
Cerebral white matter

L

-27

-24

33

236

R

22

11

-4

116

R

10

-30

65

104

R

61

-15

2

64

L

-22

10

-6

49

L

-10

-31

64

45

R

25

-9

-18

43

R

25

29

18

40

L

-27

-11

-17

33

R

26

1

35

20

L

-46

-27

54

814

B

-1

18

48

223

R

19

-55

-21

144

L

-46

18

-2

106

4
5
6
7
8
9
10
11
12

NoGo-Error (E > C)

5

Postcentral gyrus/inferior
parietal gyrus
SMA/Pre-SMA/superior, middle
& medial frontal gyrus
Cerebellum (culmen & dentate)
Anterior Insula/inferior frontal
gyrus (IFG)
Thalamus

L

-10

-23

8

75

6

Precentral gyrus

L

-56

8

31

66

7

Cerebellum
Anterior Insula/inferior frontal
gyrus (IFG)
Postcentral gyrus
Middle insula/frontal opercular
area

R

17

-66

-54

57

R

53

18

0

41

R

61

-16

35

34

L

-45

-4

12

21

1
2
3
4

8
9
10

NOTE. Regions showing greater activation during successful (NoGo-correct) and failed
(NoGo-error) NoGo trials. Whole-brain, one-sample t-test (two-tailed, 3dTtest++),
thresholded at pvoxel-wise=1.0e-10, cluster extent: 20 voxels (arbitrarily chosen). n=103: 6
participants from the total sample (n=109) were excluded because they did not meet task
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performance criteria (more than 50% Go-errors). Voxel size: 3.44 x 3.44 x 3.40 mm3. X:
Left (-), Right (+); Y: Posterior (-), Anterior (+); Z: Inferior (-), Superior (+). Region labels
come from the AFNI Talairach daemon atlas. See main text Figure 2A for graphical
representation.
Table S8. Error awareness cluster coordinates.

Region

Hemisphere

Center
Coordinates
(MNI, LPI)
X
Y
Z

Cluster Size
(# of Voxels)

Aware NoGo-errors (A > U)

2

Postcentral, Precentral & inferior
parietal gyrus
Cerebellum (vermis)

B

0

46

0

1440

3

Thalamus, putamen, posterior insula

R

0

39

4

586

4

Postcentral gyrus

R

45

39

65

487

5

Anterior insula/inferior frontal gyrus

R

59

-16

-3

179

6

B

0

29

27

92

R

28

-2

-10

71

8

Middle cingulate cortex
Ventral striatum (putamen, nucleus
accumbens)
Superior parietal gyrus (precuneus)

R

7

77

55

45

9

Superior frontal gyrus

R

35

-54

31

39

10

Superior frontal gyrus

L

-34

-54

27

34

11

Middle posterior temporal gyrus

R

66

53

4

7

28

-30

58

40

1

7

B

-38

25

72

2330

Unaware NoGo-errors (U > A)
1

Middle frontal gyrus

R

2

Inferior frontal gyrus (orbitalis)

R

42

-40

-17

18

3

Superior frontal gyrus

4

Inferior frontal gyrus (triangularis)

L
R

-24
52

-37
-26

48
14

18
12

5

Posterior cingulate cortex

R

11

56

14

11

6

Superior parietal gyrus (precuneus)

L

-48

-77

41

10

7

Posterior cingulate cortex

L

-10

-56

10

8

NOTE. Regions showing greater activation during aware and unaware errors on NoGo
trials. Whole-brain, one-sample t-test on NoGo-error: Aware minus NoGo-error: Unaware
[A-U] contrast values (pFWE-corrected <0.05; pvoxel-wise<0.0001, cluster extent: 7 voxels,
3dClustSim with spatial autocorrelation correction). n=86: 23 participants from the total
sample that either did not meet task performance criteria (more than 50% Go-errors) or did
not commit at least 2 of each type of NoGo-error (aware and unaware) were excluded.
Voxel size: 3.44 x 3.44 x 3.40 mm3. X: Left (-), Right (+); Y: Posterior (-), Anterior (+);
Z: Inferior (-), Superior (+). Region labels come from the AFNI Talairach daemon atlas.
See main text Figure 3A for graphical representation.
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Table S9. Main effect of HIV serostatus cluster coordinates.
Region

Hemisphere

Center Coordinates
(MNI, LPI)
X
Y
Z

Cluster Size
(# of Voxels)

HIV main effect
1

Medial prefrontal cortex (mPFC)

B

2

65

-2

39

2

Posterior cingulate cortex (PCC)

B

2

-51

29

36

NOTE. Regions showing significant HIV main effects in a whole-brain, HIV x CB
ANOVA (3dMVM) assessing cognitive-control/failure [C-E] activation maps (pFWEcorrected<0.05; pvoxel-wise<0.001, cluster extent: 35 voxels). n=103: 6 participants from the
total sample that did not meet task performance criteria (more than 50% Go-errors) were
excluded. Voxel size: 3.44 x 3.44 x 3.40 mm3. X: Left (-), Right (+); Y: Posterior (-),
Anterior (+); Z: Inferior (-), Superior (+). Region labels come from the AFNI Talairach
daemon atlas. See main text Figure 4A for graphical representation.

Figure S1. Error awareness brain activity in HIV-positive and HIV-negative groups.
At the whole-brain level, no significant group effects on aware vs. unaware error [A-U]
contrast images were detected. However, follow-up exploratory analyses on average [A]
and [U] b coefficients extracted from PCC and mPFC ROI masks were conducted. (A) 3way 2(HIV: positive vs. negative) x 2(CB: user vs, nonuser) x 2(AWARENESS: aware vs.
unaware) ANOVAs were conducted separately for each ROI (n=86) Similar to the
inhibition analyses reported in the main text (main text Fig. 4A), no significant HIV x CB
interaction or CB main effects were observed; however, both the PCC (F[1, 82] = 4.8,
p=0.03) and mPFC (F[1, 82] = 7.6, p=0.007) displayed a significant main effect of
AWARENESS such that both regions displayed increased deactivation during aware errors
relative to unaware errors. Further, consistent with the HIV main effect on brain
deactivation during all errors (main text Fig. 4A), both regions also displayed a significant
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main effect of HIV such that, HIV- controls had increased deactivation in the PCC (F[1,
82] = 7.0, p = 0.01) and mPFC (F[1, 82] = 10.4, p = 0.002) compared to the HIV+
individuals. While these results indicate significantly less PCC and mPFC deactivation
among the HIV+ group during both aware and unaware errors, the nonsignificant HIV x
AWARENESS interactions (p’s>0.6) denote that both HIV- and HIV+ groups display a
similar difference between aware and unaware error brain activity. (B: n=86) When
assessing relations to task behavior we observed significant HIV by ERROR-COUNT
interactions on PCC activity during aware errors (F[1, 82]=8.9, PBonferronni-corrected = 0.008)
similar to interaction effects on PCC activity during all errors that was reported in the main
text (main text Fig. 4C). Follow-up conditional effects within each group indicated that,
among HIV+ participants, increased PCC deactivation during aware errors was
significantly associated with worsened cognitive control task performance (more NoGoerrors; p=0.02). (C: n=86) We also observed significant HIV by ERROR-COUNT
interactions on PCC activity during and unaware errors (F[1, 82]=6.4, PBonferronni-corrected =
0.02). Follow-up conditional effects within each group indicated that, among HIVcontrols, increased PCC deactivation during unaware errors was associated with better
cognitive control task performance (fewer NoGo-errors) whereas, among HIV+
participants, increased PCC activity during aware errors was associated with worsened
cognitive control task performance. (D: n=86) We observed null effects of behavioral error
awareness performance (%UNAWARE) on brain activity during aware errors (p’s>0.1).
(E: n=86) We observed a significant main effect of awareness performance on mPFC brain
activity during unaware errors such that decreased mPFC activity during unaware errors
was linked to a higher percent of unaware errors (F[1, 82]=5.8, PBonferronni-corrected = 0.02).
Follow-up conditional effects within each group indicated that this main effect of error
awareness performance on mPFC unaware activity was primarily displayed among HIVcontrols (p=0.01).

Figure S2. Impact of chronic CB use on brain activity. To assess the impact of selfreported amount of CB used over the lifetime (LIFETIME-AMOUNT) and the impact of
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total times using CB (LIFETIME-USES) on HIV-associated functional brain alterations,
we conducted exploratory HIV x LIFETIME-AMOUNT and HIV x LIFETIME-USES
ANCOVAs on task-related bs (NoGo-error and NoGo-correct) averaged across voxels in
ROIs displaying a significant main effect of HIV, among CB using participants (n=55).
Past month amount of nicotine used and past month times using nicotine variables were
included as covariates in these analyses. As the LIFETIME-AMOUNT and LIFETIMEUSE variables were skewed to the right, both were log10 transformed before conducting
statistical tests. (A) During error-NoGo trials: among HIV- users, but not PLWH users,
more times using CB over the lifetime (b=1.2, t[24]=2.2, p=0.04) was significantly linked
to reduced deactivation in the mPFC. A similar, albeit nonsignificant pattern was observed
for HIV- controls’ amount of cannabis used over the lifetime (b=0.7, t[24]=2.0, p=0.06).
(B) During correct-NoGo trials: among HIV- CB users, but not PLWH users, both times
using CB over the lifetime (b=1.5, t[24]=3.2, p=0.003) and amount of CB used over the
lifetime (b=0.7, t[24]=2.3, p=0.03) were significantly associated with reduced deactivation
in the mPFC. No significant effects of LIFETIME-USES or LIFETIME-AMOUNT on
PCC activity were observed.
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Appendix 2: Supplemental Material for Chapter 2
Table S1. Participant mental health status by group: Sample with resting-state data.
All
Participants
n=93

HIV+/CB+
n=28

HIV+/CBn=26

HIV-/CB+
n=22

HIV-/CBn=17

10

4

3

1

2

0.4

0.8

22

11

3

4

4

0.5

0.1

Major Depressive
Episode (current)
Major Depressive
Episode (past)

Group Effects
(p’s)
HIV
CB

NOTE. Mental health status is reported as count of participants meeting criteria for a
current or past Major depressive episode as assessed via the Structured Clinical Interview
for DSM-5 Research Version (SCID-5-RV). Participants were excluded from the sample
if they presented severe mental illnesses with psychotic or paranoid symptoms. Group
effects were assessed with two Chi-square tests, one comparing the HIV+ versus HIVgroups and the other comparing the CB+ versus CB- groups.
Table S2. Participant plasma THC levels by group: Sample with resting-state data.
All CB+ Participants
n=47

HIV+/CB+
n=28

HIV-/CB+
n =22

Group
Effects (p’s)

761.9 (1,145.5)

964.6 (1,403.4)

503.9 (636.4)

0.1

599.5 (690.8)

622.0 (728.0)

566.5 (650.1)

0.8

9-carboxy-THC (ng/mL)
THC/creatinine ratio (ng/mg)

NOTE. Data are expressed as mean (standard deviation). Group effects were assessed with
an independent samples t-test comparing cannabis using participants that were HIV+
versus HIV-.
Table S3. Drug dependence status by group (count): Sample with resting-state data.
All
Participants
n=93

HIV+/CB+
n=28

HIV+/CBn=26

HIV-/CB+
n=22

HIV-/CBn=17

10

6

0

4

17

8

0

Alcohol (lifetime)

10

3

Cocaine (lifetime)
Other stimulants
(lifetime)
Opiates (lifetime)
Other sedatives
(lifetime)
Hallucinogens
(lifetime)

8

3

3

Cannabis (past
month)
Cannabis (lifetime)

Group Effects (p’s)
HIV

CB

0

0.9

0.002

9

0

0.4

<0.001

2

3

2

0.7

0.7

1

3

1

0.7

0.3

3

0

0

0

-

-

1

1

0

0

0

-

-

2

2

0

0

0

-

-

2

2

0

0

0

-

-
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Other drug
(lifetime)

2

1

0

1

0

-

-

NOTE. Drug dependence data are expressed as the count of participants meeting
dependency criteria either ever (lifetime) or in the past month (past month), as defined in
the DSM-5 Structured Clinical Interview. As current (past month) drug dependence was
exclusionary criteria (except cannabis dependence in the CB+ groups), no participants met
dependency criteria in the past month for any of the reported drugs. Group effects were
assessed with two Chi-square tests, one comparing the HIV+ vs. HIV- groups and one
comparing the CB+ vs. CB- groups. These analyses were not performed when data did not
meet criteria for Chi-square tests (cells with <5 observations).
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Table S4. Past month and lifetime drug use: Sample with resting-state data.

Cannabis (past month)

All Participants
n=93
12.8 (14.0)

HIV+/CB+
n=28
23.4 (9.8)

HIV+/CBn=26
0

Cannabis (lifetime)

2,140.7 (3,111.6)

3,556.8 (2968.6)

282.6 (1024.1)

2.2 (3.3)

2.2 (2.6)

2.2 (4.2)

1,110.9 (1,557.3)

1,128.1 (1,498.8)

1,314.0 (1,918.0)

Alcohol (past month)
Alcohol (lifetime)
Cocaine (past month)
Cocaine (lifetime)
Nicotine (past month)

0.02 (0.1)

0.1 (0.3)

0

HIV-/CB+
n=22
24.4 (10.1)
4,182.5
(3,852.1)
2.9 (3.2)
1,369.4
(1,574.5)
0

HIV-/CBn=17
0

Group Effects
HIVxCB
HIV
CB
p=0.7
p=0.7
p<0.001*

0

p=0.2

p=0.2

p=0.2

268.8 (917.9)

260.5 (836.0)

430.7 (1,267.3)

289.0 (890.0)

8.9 (29.4)

p=0.3

p=0.3

p=0.8

4.3 (10.2)

7.2 (12.7)

1.5 (6.0)

0

p=0.7

p=0.7

p=0.002*

1614.0 (3,205.1)

1,965.0 (2,805.6)

1,575.0 (4,198.9)

172.6 (607.8)

p=0.2

p=0.4

p=0.06

7.8 (23.7)

p=0.4

p=0.7

p<0.001*

1.4 (2.9)

p=0.3

p=0.9

p=0.3

437.2 (714.9)

p=0.1

p=0.3

p=0.3

Methamphetamine (past month)

0.02 (0.2)

0.1 (0.4)

0

7.2 (12.8)
2,327.1
(3,351.5)
0

0

p=0.4

p=0.4

p=0.4

Methamphetamine (lifetime)
Prescription stimulants (past
month)
Prescription stimulants (lifetime)

21.2 (126.9)

60.2 (222.7)

0

13.1 (61.4)

0

p=0.4

p=0.4

p=0.2

0.02 (0.2)

0

0

0.1 (0.4)

0

p=0.3

p=0.3

p=0.3

25.5 (224.2)

80.0 (407.8)

0

6.0 (25.5)

0

p=0.4

p=0.4

p=0.4

Nicotine (lifetime)

Heroin (past month)

0

0

0

0

0

-

-

-

0.01 (0.1)

0

0

0.05 (0.2)

0

p=0.3

p=0.3

p=0.3

0

0

0

0

0

-

-

-

Opiates (lifetime)

13.1 (83.2)

29.5 (135.8)

0

17.2 (76.7)

0.7 (2.9)

p=0.7

p=0.7

p=0.2

Benzodiazepines (past month)

0.01 (0.1)

0

0

0.04 (0.2)

0

p=0.3

p=0.3

p=0.3

Benzodiazepines (lifetime)

39.5 (273.4)

128.8 (492.8)

0

2.6 (6.5)

0

p=0.3

p=0.3

p=0.3

Barbiturates (past month)

0

0

0

0

0

-

-

-

7.6 (51.8)

11.6 (61.2)

0

0.04 (0.2)

0

p=0.9

p=0.2

p=0.9

Heroin (lifetime)
Opiates (past month)

Barbiturates (lifetime)
Ecstasy (past month)
Ecstasy (lifetime)

0

0

0

0

0

-

-

-

32.1 (100.6)

67.1 (156.9)

0.3 (1.6)

49.5 (93.1)

0.5 (1.5)

p=0.7

p=0.7

p=0.006*

Inhalants (past month)

0.02 (0.2)

0.1 (0.4)

0

0

0

p=0.4

p=0.4

p=0.4

Inhalants (lifetime)

13.8 (77.8)

43.1 (138.6)

14.8 (75.3)

3.2 (13.8)

0

p=0.2

p=0.2

p=0.2
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Ever injection drug use (count)

1

1

0

0

0

-

-

-

NOTE. Data are expressed as mean (standard deviation). Drug use was self-reported as the number of “times” using each drug in
the given timeframe (past month or lifetime) on the National Survey on Drug Use and Health. Group effects were assessed with
either an HIV x CB ANOVA or Chi square tests. * p < 0.05.
Table S5. Group differences in sensory and motor processing.
All Participants
n=93

HIV+/CB+
n=28

HIV+/CBn=26

HIV-/CB+
n=22

HIV-/CBn=17

HIV

Group Effects (p’s)
CB
HIV x CB

55.1 (6.7)

59.7 (8.2)

53.0 (5.1)

53.7 (4.8)

52.7 (5.2)

0.02*

0.005*

0.03*

Dominate Hand GPT

45.1 (11.2)

45.7 (7.6)

45.4 (13.3)

44.2 (12.6)

45.0 (11.3)

0.75

0.72

0.71

Non-dominate Hand GPT

44.1 (9.6)

43.7 (8.8)

44.4 (10.2)

45.5 (11.2)

42.6 (8.2)

0.99

0.62

0.44

Sensory Processing
Somatic Complaints
Motor Performance

NOTE. Data are expressed as mean (standard deviation). Group effects were assessed with HIVxCB ANCOVAs with age, sex, and
cigarette smoking (NIC) status included as covariates. No group differences were detected for IQ and GPT scores. Somatic
complaints were assessed as t-scores on the DSM-oriented somatic problems subscale of the Adult Self-Report (ASR) survey,
corrected for age and biological sex based on national probability samples. GPT = t-scores on Grooved Pegged Board Test, corrected
for age and biological sex based on test norms.
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Table S6. Cluster coordinates for left anterior dorsal insula HIV and CB effects.

Region

Hemisphere

Center
Coordinates
(MNI, LPI)
X
Y
Z

Cluster Size
(# of Voxels)

Left Dorsal Anterior Insula Connectivity
HIV x CB effect
1

Postcentral, precentral & inferior
parietal gyrus

R

53

-18

39

76

L

-1

-79

36

64

CB main effect
1

Parietal-occipital sulcus

NOTE. Regions showing significant HIVxCB interaction on resting-state functional
connectivity (rsFC) strength with the left dorsal anterior insula (n=93). Thresholded at
pFWE-corrected <0.05, pvoxel-wise=0.001 with cluster extent threshold of 37 voxels, determined
using 3dClustSim with spatial autocorrelation correction. Voxel size: 2 x 2 x 2 mm. X: Left
(-), Right (+); Y: Posterior (-), Anterior (+); Z: Inferior (-), Superior (+). Region labels
come from the AFNI Talairach daemon atlas.
Table S7. Cluster coordinates for right ventral anterior insula HIV and CB effects.

Region

Hemisphere

Center
Coordinates
(MNI, LPI)
X
Y
Z

Cluster Size
(# of Voxels)

Right Ventral Anterior Insula Connectivity
HIV x CB effect

2

Supplementary motor area, medial
frontal gyrus
Paracentral gyrus

3

Superior temporal gyrus

4

Primary motor area

1

R

11

-17

70

102

R

8

-37

71

70

R
R

65
29

-56
-20

9
75

67
39

HIV main effect
1

Middle temporal gyrus

R

62

-55

7

245

2

Superior parietal gyrus

R

41

-56

61
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3

Postcentral gyrus

L

-59

-37

56

71

4

L

-54

31

29

50

R

38

-47

-3

42

6

Lateral middle frontal gyrus
Cerebral white
matter/parahippocampus gyrus
Postcentral gyrus

R

57

-29

56

42

7

Lateral middle frontal gyrus

R

53

44

14

40

5
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8

Postcentral/superior parietal gyrus

L

-34

-46

73

40

9

Superior frontal gyrus

R

35

4

64

36

CB main effect
1

Middle temporal sulcus

L

-56

-48

7

82

2

Lateral middle Frontal gyrus

R

49

49

13

77

3

Inferior parietal gyrus

L

-56

-39

59

73

4

Superior temporal gyrus

R

59

-10

6

65

5

Middle occipital gyrus

R

53

-73

2

64

6

Middle occipital gyrus

L

-54

-76

0

61

7

Inferior parietal gyrus

R

53

-45

59

59

8

Posterior superior temporal gyrus

R

65

-56

9

54

9

Superior parietal gyrus

R

31

-63

65

54

10

L

-30

-78

-57

52

L

-22

-55

67

50

12

Cerebellum (inferior semi-lunar lobe)
Postcentral gyrus, superior parietal
gyrus
Cerebellum (declive)

L

-22

-68

-23

47

13

Lateral postcentral gyrus

L

-63

-25

34

45

14

Lateral inferior parietal gyrus

L

-54

-32

40

41

15

Precentral gyrus
Postcentral gyrus, superior parietal
gyrus

R

58

-4

48

39

R

24

-56

71

39

11

16

NOTE. Regions showing significant HIVxCB interaction on resting-state functional
connectivity (rsFC) strength with the right ventral anterior insula (n=93). Thresholded at
pFWE-corrected <0.05, pvoxel-wise=0.001 with cluster extent threshold of 36 voxels, determined
using 3dClustSim with spatial autocorrelation correction. Voxel size: 2 x 2 x 2 mm. X: Left
(-), Right (+); Y: Posterior (-), Anterior (+); Z: Inferior (-), Superior (+). Region labels
come from the AFNI Talairach daemon atlas.

Figure S1. Insula subregion three-dimensional rendering. The dorsal anterior insula
(DI; yellow), ventral anterior insula (VI; blue), and posterior insula (PI; green), in both the
right and left hemisphere, were defined using Chang and colleagues (2013) parcellation
based on coactivation during a variety of tasks and rsFC patterns across the literature. These
seeds were then thresholded at 0.85 probability, as described in Fedota et al., (2018).
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Appendix 3: Supplemental Material for Chapter 3

Figure S1. HIV main effect on ICA-derived network rsFC. To better control the spatial
coverage of networks across participants we employed the atlas-based approach, described
in the main text, to calculate our resource allocation indexes (RAIs) rather than an
independent component analysis (ICA)-based approach that has been used in prior work.
The lack of between-participant variability in network definition, allowed for the results
from our group comparisons to be interpreted as differences in rsFC strength rather than
differences in spatial topology of networks. Additionally, as we had a priori hypotheses
regarding regions that may be impacted by HIV based on prior work implicating anterior
insula and supplementary motor area regions of the salience network (SN) and the middle
medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), and hippocampus
regions of the default mode network (DMN), we wanted to ensure that our network masks
included these regions. Thus, we used the FIND Lab’s anterior (anterior insula / dorsal
ACC) SN subnetwork mask and dorsal (PCC / mPFC) DMN subnetwork. However, as
prior work calculating RAIs has employed an ICA-based approach to first, identify
networks and estimate participant-specific timeseries, we also employed an ICA-based
approach.
Specifically, we calculated our RAIs using networks identified via a group-average
ICA (GICA). Participants’ preprocessed function data was entered into a GICA using
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MELODIC’s temporal concatenation decomposition (FSL v.0.6.4) with a model order of
20. (A) The resulting thresholded GICA spatial maps that corresponded to the SN, DMN,
left central executive network (L.CEN), and right CEN (R.CEN) were identified by visual
inspection. GICA component maps of interest were then regressed on each participant’s
functional data as spatial predictors, to generate participant-specific timeseries for each
network using dual_regression (FSL v.0.6.4). These network timeseries were then used to
calculate RAI values. Standardized correlation coefficients (CCs) between these ICAderived network timeseries and RAIs were computed using the same approach as was
applied for the atlas-based timeseries. RAIs derived via the ICA-based method were highly
correlated with those derived with the atlas-based method (right: p<0.0001, left: p=0.017),
albeit displayed more variability across subjects (standard deviation: ICA-based=0.36
[left], 0.33 [right] vs. atlas-based=0.24 [left], 0.22 [right]).
(B1) We assessed HIVxCB main and interaction effects with general linear models
(GLM) including age, sex, mean framewise displacement (FD), and current cigarette
smoking (NIC) status included as covariates. These GLMs were equivalent to the analyses
run on RAIs and network resting-state functional connectivity (rsFC) measures derived
from atlas-based approach described in the main text. PLWH had a significantly reduced
RAI compared to HIV- participants in the left hemisphere (HIV main effect: F[1, 92]= 5.9,
p=0.017). (B2) However, unlike the RAI computed via the atlas-based approach, no
significant group effects were observed for the RAI in the right hemisphere (F[1, 92]=0.4,
p=0.2). (B3) While, visual inspection suggests similar non-significant trends in SN-DMN
rsFC across HIV and CB groups as those observed on atlas-derived measures, group-effects
did not reach significance (p’s>0.3). (B4) PLWH displayed significantly reduced SNL.CEN connectivity compared to HIV- participants (F[1, 92]=4.2, p=0.04). (B5) We did
not observe any significant group-effects on SN-R.CEN rsFC (p’s>0.8). (C) Group-effects
on atlas-derived network connectivity measures reproduced for comparison.
Unstandardized residuals after regressing out covariates are plotted. Error bars = standard
error of the mean.

Figure S2. ICA-derived network rsFC linked with error awareness. (A) Relationships
between ICA-derived RAIs, network rsFC, and frequency of unaware errors (error
awareness). A negative binomial model (R, v.4.0.2) was used to statistically test these
relationships as the error awareness variable was a positively skewed count variable and
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thus, did not meet assumptions required for linear regression [276]. Age, sex, mean FD,
and NIC status were included as covariates in these analyses (n=86). A negative binomial
model was selected over a Poisson model as the formal test of dispersion indicated that the
unware error count variable was overdispersed. Decreased left RAI (L.RAI) was
significantly associated with increased unaware errors (negative binomial model [n=86]:
b=-0.99, z=-2.4, p=0.017). Contrarily, RAI from the right hemisphere (R.RAI; b=-0.6, z=1.4, p=0.2), SN-DMN rsFC (b=0.6, z=1.3, p=0.2), SN-L.CEN rsFC (b=-1.1, z=-1.9,
p=0.06), and SN-R.CEN rsFC (b=-0.2, z=-0.2, p=0.8) were not significantly associated
with error-awareness. (B) Relationships between atlas-derived RAIs, network rsFC, and
error awareness reproduced for comparison. Unstandardized residuals after regressing out
covariates are plotted.
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